Studies Towards the Development of a Novel Anti-Cancer Agent by Coll, Jacqueline
STUDIES TOWARDS THE
DEVELOPMENT
OF A
NOVEL ANTI-CANCER AGENT
A thesis presented in part fulfilment of the requirements for the Degree of
Doctor of Philosophy 
by
Jacqueline Coll
Department of Chemistry 
The University 
Glasgow
August 1993
ProQuest Number: 13832065
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13832065
Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
R-isri
Neves'
fGLASGOW  I 
I UNIVERSITY I 
I LIBRARY
ACKNOWLEDGEMENTS
A big thank you to Dr. Bob Hill for his help and support. Thanks also to 
Graham and Mycology staff, especially Pearl.
Making the whole thing easier also thanks to Fran, Debs, Gail, Aileen, Janette, 
Steph and everyone else whose support I appreciated.
Thanks mum and dad for being there and being brilliant throughout 
everything.
Financial support from S.E.R.C. is acknowledged, as is C.R.C. funding of 
oncology and biochemical work.
Finally, thank you Duncan, for being understanding, patient and knowing just 
a wee bit about Chemistry. Lots of love.
To Mum and Dad.
SUMMARY
This project has been a collaborative effort involving the design, synthesis and testing 
of analogues of the fungal metabolites viridin, demethoxyviridin and wortmannin. 
Extraction methods of viridin, from Trichoderma viride were developed and initially 
provided a lead compound for testing. Data relating to the anti-inflammatory activity 
of wortmannin analogues was available in the literature and was used in a computer 
modelling program SYBYL to build a structure activity relationship from which 
activity of new analogues could be predicted. The crystal structure determination of 
demethoxyviridin provided detailed structural information about these molecules. 
This was used in modelling studies to guide the synthesis of new compounds, leading 
to the synthesis of an analogue several hundred times more active than the original 
lead compound. A patent has been applied for this compound and it is presently being 
forwarded for cinical trials in animals for toxicity testing. The compounds were 
shown to be cytotoxic in vitro and inhibit specific enzymes in the signal transduction 
pathway. Preferential inhibition of mitogen stimulated cells was shown, indicating 
that some degree of selectivity was built into the molecules, suggesting that future 
compounds may have relatively few side effects due to their novel mechanism of 
action.
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CHAPTER 1 
INTRODUCTION
1CANCER - PRESENT STAGE
Cancer is now one of the leading causes of death world-wide1. The emerging 
role for cancer as a cause of mortality is due not so much to continuing 
increases in cancer mortality but to the remarkable and consistent decline in 
heart disease mortality over the past four decades, due perhaps to a 
combination of a reduced prevalence of major risk factors (altered lifestyle, 
better detection and treatment of hypertension, etc.) and improved treatment of 
the various clinical manifestations of heart disease. As such, heart disease can 
serve as a model for the impact of a combination of altered lifestyle and 
improved treatment on mortality, which will hopefully soon be applied to 
cancer.
Since 1973 increases in mortality of greater than 15% have occurred for lung 
cancer, melanoma, non-Hodgkin's lymphoma, and multiple myeloma. 
Increases in cigarette smoking from 1900 until the early 1960s transformed 
lung cancer from a rare disease at the turn of the century to the current leading 
cause of cancer death. The annual mortality rate of lung cancer in men has 
finally levelled off after more than 50 years of unabated increase. In women, 
lung cancer surpassed breast cancer as the leading cause of cancer death in 
1986, these rates are expected to continue to increase for at least another 10 
years. The increase in melanoma mortality parallels a larger increase in the 
incidence of this disease, mainly caused by increased sunbuming in fair 
skinned populations, attributable to changing fashions and recreational habits 
and also the recent much publicised depletion of the ozone layer.
The increase in mortality from, and the increased incidence of, non-Hodgkin's 
lymphoma and multiple myeloma remain largely unexplained. Improved 
diagnostic procedures may be part of the reason for this increase in 
lymphoproliferative diseases. Immunocytochemistry can distinguish genuine
2lymphomas from undifferentiated epithelial tumours that have metastasised to 
lymph nodes from unknown primary sites, and distinguish more definitely 
extra nodal primary lymphomas from cancers of other histologies that occur at 
the same site. In younger age groups, however, much of the recent increased 
incidence of certain types of lymphomas is due to the increased prevalence of 
human immunodeficiency virus (HTV) infection, which is an established cause 
of these cancers.
WHAT CAUSES CANCER?
Most recognised cancer causing substances have either direct genotoxic 
effects on DNA (e.g. radiation) or increase cell proliferation (e.g. hormones) 
or a combination of both (e.g. tobacco)2.
Increased cell proliferation appears to be the most important. Molecular 
genetics has provided evidence that cell division is essential for the genesis of 
human cancer and that an increased rate of cell division will increase cancer 
risk. 'Increased' may imply mitotic activity above the baseline rate or a 
division of a subset of cells that would ordinarily not be dividing. Cell 
division increases the risk of genetic errors of various kinds. Adducts or other 
single-stranded DNA damage may be converted to gaps or mutations, and 
mitotic recombination may result in more profound changes than those from a 
single mutation. The development of a fully malignant tumour appears to 
involve multiple stages - the activation or altered expression of proto- 
oncogenes and the loss or inactivation of tumour suppresser genes, which 
control normal cellular activity. The activation of proto-oncogenes, whether 
by mutation, translocation, or amplification, requires cell division. 
Inactivation of a tumour suppresser gene appears to involve first a mutational 
event that inactivates one allele, followed by a deletion during mitosis that
3results in homozygosity. Both the fixation of the initial mutagenic event and 
the loss of the wild-type allele of the tumour suppresser (e.g. a hormone) can 
act at all stages in the pathogenesis of a malignant phenotype. Removal of the 
causative agent (except very late) can prevent or delay full development of the 
cancer.
Chemical and physical carcinogens leave traces of their activities on DNA 
because of the specific patterns of base changes they induce. Knowledge of 
the mutation patterns in genes believed to be involved in human cancer might 
be able to be used to predict the likelihood that an exogenous DNA damaging 
agent may be involved. It may ultimately be possible to predict what the agent 
might be. For example, liver mutations typically are found at one nucleotide 
pair of codon 249 of the tumour suppresser gene p53 in liver cancers 
occurring in individuals who live in geographic areas where exposure to both 
aflatoxin and hepatitis B (a probable and an established cause of liver cancer, 
respectively) is common.
CURRENT TREATMENT
Despite a vast array of drugs now available to treat cancer, one main drawback 
exists in a lack of selectivity, i.e. toxic side effects. Most drugs interfere with 
the role of nucleic acids, blocking cell division. The synthetic phase of the cell 
cycle is affected thus cell populations with a high mitotic index are most 
susceptible, e.g. rapidly dividing malignant cells, bone marrow, gonads, 
gastro-intestinal tract lining, hair follicles etc. The primary aim of 
chemotherapy is to prolong life, but treatment should be as free as possible 
from pain and distressful side effects, thus optimum chemotherapy should 
encompass a drug, or a range of mutually beneficial drugs which are potent, so 
that doses can be low, and free from toxicity, i.e. as selective as possible. The
4particular type of cancer would also dictate the chemotherapeutic approach, 
e.g. lung cancer, the commonest carcinoma, is relatively slow growing but 
acute leukaemia cells are rapidly dividing.
Two main classes of product are used for the chemotherapy of neoplastic 
disorders, the cytotoxic drugs and the sex hormones3.
CYTOTOXIC DRUGS
Cytotoxic drugs can be divided into 5 main groups;
1. Alkylating drugs
2. Cytotoxic metabolites
3. Antimetabolites
4. Vinca alkaloids and etoposide
5. 'Others'
Malignant disease is treated by surgery, radiotherapy, and/or chemotherapy. 
Certain tumours are highly sensitive to chemotherapy but many are not, and 
inappropriate drug administration in these circumstances can only increase 
morbidity.
All of these drugs are designed to stop cell division in cancer cells. However, 
normal cells, particularly those with a rapid rate of mitosis, can also be 
affected. Toxic effects commonly observed are severe nausea and vomiting, 
alopecia and bone marrow suppression. Myelosuppression necessitates 
checking blood counts prior to each stage of treatment, with the dosage 
modified or treatment being delayed accordingly.
51. The alkylating drugs are among the most extensively used in cancer 
chemotherapy. They act by damaging the DNA, thus interfering with cell 
replication. They are not entirely selective for the cancer cells thus have many 
side effects. These include extravasation, i.e. leakage of the drug into the 
extravascular compartment causing severe tissue necrosis, hypercalcaemia, 
hyperuricaemia which can result in uric acid crystal formation in the urinary 
tract and associated renal dysfunction, nausea and vomiting, bone marrow 
suppression, alopecia and interference in reproductive function. Although 
many of these side effects are associated with most of the cytotoxic drugs, 
there are two main problems associated with long term usage of alkylating 
drugs. Firstly, gametogenesis is often severely affected and secondly, 
prolonged use of these drugs, particularly when combined with extensive 
radiation, is associated with a marked increase in the incidence of certain 
types of cancer, i.e. of acute non-lymphocytic leukaemia. These drugs include 
cyclophosphamide, chlorambucil and busulphan.
2. Cvtotoxic antibiotics are also widely used. Many act as radiomimetics so 
simultaneous use of radiotherapy is avoided as it can result in markedly 
enhanced tissue toxicity. Doxorubicin is one of the most successful drugs, 
and is used to treat the acute leukaemias, lymphomas and a variety of solid 
tumours. It can be cardiotoxic at high doses so care is needed when treating 
patients with previous history of heart disease. Epirubicin is structurally 
related to doxorubicin and is thought to be slightly less cardiotoxic. 
Bleomycin is used to treat the lymphomas, certain solid tumours and 
malignant effusions. Dermatological toxicity is common, as is mucositis and 
an association with R aynaud's phenomenon - an attack of marked 
vasoconstriction of the extremities, affecting the hands and feet giving rise to 
tingling, pain and sometimes ischaemic damage. Hypersensitivity reactions 
are shown by chills and fevers commonly occurring a few hours after drug
6administration, but which may be prevented by concurrent administration of a 
steroid, e.g. hydrocortisone.
3. Antimetabolites are incorporated into new nuclear material or combine 
irreversibly with vital cellular enzymes, preventing normal cell division. 
Methotrexate inhibits the enzyme dihydrofolate reductase, essential for the 
synthesis of purines and pyrimidines. It can cause m yelodepression, 
mucositis and rarely pneumonitis. It is contra-indicated if significant renal 
impairment is present as the kidney is the route of excretion. Folinic acid 
('rescue') is given to speed recovery from methotrexate toxicity. Other 
antimetabolites include fluorouracil, and mercaptopurine.
4. Vinca alkaloids and etoooside interfere with microtubule assembly, causing 
metaphase arrest. All vinca alkaloids have similar activity but vary in the site 
of toxicity. Vincristine and vinblastine are commonly associated with 
peripheral and autonomic neuropathy shown by peripheral paraesthesia 
and loss of deep tendon reflexes. Recovery of the nervous system in these 
cases is generally slow but complete. Etoposide is used to treat small cell 
carcinoma of the bronchus, the lymphomas and testicular teratoma.
5. "Others' include carboplatin, cisplatin and procarbazine. Carboplatin is a 
derivative of cisplatin with similar activity although it appears to be better 
tolerated in some ways, i.e. less nausea, vomiting, nephrotoxicity and 
neurotoxicity although it is more myelosuppressive and for this reason is not 
used more frequently than 4 week intervals. Cisplatin is an alkylating type 
drug but is extremely toxic. Procarbazine is a first line treatment in Hodgkin's 
disease. Toxic effects include rash. It is also a mild monoamine oxidase 
inhibitor.
7SEX HORMONES
The sex hormones and antagonists are mainly used for the treatment of 
prostatic and breast cancer. Hormonal treatment of advanced prostatic cancer 
is based on the concept that hormone-dependent neoplasms will regress when 
deprived of hormonal stimulation. In prostatic carcinoma, which in general is 
androgen dependent, oestrogens are often effective but their use is limited by 
cerebral and cardiovascular side effects. The anti-androgen cyproterone 
acetate blocks adrenal and testicular androgens which provide the androgenic 
stimulus to the prostrate. This is a more rational form of treatment for 
prostatic cancer and has produced responses in patients who have relapsed 
after oestrogen therapy and orchidectomy. Gynaecomastia is less of a problem 
and the cardiovascular risk is decreased. Flutamide is also an anti-androgen 
which acts by inhibiting androgen uptake and/or by inhibiting nuclear binding 
of androgens in target tissue. In advanced prostatic cancer, flutamide produces 
a response which is comparable to that achieved with oestrogen therapy and 
when used in combination with a LHRH (luteinising hormone releasing 
hormone) agonist, survival rate is prolonged. GnRH (gonadotrophin releasing 
hormone) analogues such as buserelin, goserelin and leuprorelin are also 
effective and are also without the limiting side effects of the oestrogens. They 
produce a down-regulation of the receptors in the pituitary, preventing LH 
(luteinising hormone) release therefore decreasing serum testosterone levels. 
Anti-androgens, e.g. tamoxifen have largely replaced oestrogens for the 
treatment of advanced breast cancer especially in post menopausal women. 
Progestogens are second or third line treatment in breast cancer, and are also 
used to treat endometrial carcinoma.
8TOXICITY - RECENT ADVANCES
Selectivity for rapidly dividing cells results in many side effects, one of the 
most commonly recognised by the general public is perhaps loss of hair, 
alopecia, as a result of direct action at the hair follicles. This is often 
temporary. Some of the more serious side effects include myelodepression, 
i.e. damage to the blood forming elements of the bone marrow. Sterility and 
teratogenicity can also arise as a result of permanent damage to the gonads.
Many clinical supportive measures are used to combat such serious side 
effects. These range from simple measures such as placing ice packs on the 
patients' heads, to more sophisticated measures such as bone marrow 
transplant or use of haematopoetic growth factors.
Since 1987, a variety of these growth factors have been used to stimulate 
white blood cell growth within the bone marrow before or after treatment, e.g. 
the genetically engineered version of the natural colony stimulating factor 
'Neupogen' (g-csf) which also particularly stimulates neutrophil count. If 
bone marrow rescue becomes possible in this way, treatment can become 
bolder in terms of frequency and dosage of drug regimens. Transplants can 
become either autologous i.e. the patient donates his own bone marrow which 
is stored while he undergoes treatment, then transplanted back into the patient, 
or it can be allogenic where the tissue is a close match, e.g. from the patient's 
sibling. This is to minimise the chance of rejection or 'host-versus-graft' 
reaction. Other supportive measures such as barrier nursing, which ranges 
from the use of barrier creams to laminar air flow bed and positive pressure 
ventilation rooms, can also contribute to a successful treatment.
9One of the latest anti-cancer drugs to be released in this country is Nipent 
(containing pentostatin and deoxycoformycin). The launch was announced by 
Lederle Laboratories4 and its intended use is for first line treatment of hairy 
cell leukaemia. This is a rare, chronic leukaemia in which leukaemic cells 
have characteristic projections or 'hairs'. The disease accounts for about 2% of 
all leukaemias and mainly affects middle aged men.
Speaking at a Lederle meeting on April 15th 1993, Professor Daniel Catovsky 
(honorary consultant physician, Royal Marsden hospital, London) said that 
pentostatin was a potent inhibitor of adenosine deaminase (ADA), an enzyme 
known to play a key role in lymphocyte maturation and function. Although the 
exact mechanism of action of the drug was unclear, it was possible that in 
addition to ADA inhibition, it exerted its effects through inhibiting RNA 
synthesis and increasing DNA damage.
Another current advance is the use of high dose cytotoxics with stem cell 
transplants recently reported5. 'Is more drug better?’ is a controversial issue 
currently facing oncologists. Now that there are improved ways of reducing 
myelotoxicity, the usual dose limiting toxicity of anticancer drugs, doctors are 
able to give more intensive cytotoxic treatment, although so far there is no 
proof that high dose therapy improves survival as randomised trials have 
generally not yet been carried out.
High dose, intensive chemotherapy does, however, look very promising in 
certain types of cancer. The best results seen so far have been with diseases 
known to be responsive to chemotherapy, such as lymphoma, leukaemia, 
testicular cancer and Hodgkin's disease. This type of chemotherapy has 
become possible with the advent of improved supportive techniques -
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antibiotics, haematopoetic growth factors, bone marrow transplantation and, 
more recently, peripheral stem cell transplantation - all of whom have been 
designed to reduce myelotoxicity.
Peripheral blood stem cell transplantation is an alternative to bone marrow 
transplantation for 'rescuing* patients after bone marrow has been destroyed 
by high dose chemotherapy. The technique, which is still being evaluated, is 
known as 'off the peg' bone marrow transplantation. Blood is removed before 
the high dose chemotherapy and the stem cells are separated out, stored then 
re-infused after treatment to repopulate the bone marrow. The normal low 
yield of stem cells in the circulation is boosted by priming with mild 
chemotherapy and haematopoetic growth factors, which stimulate migration 
of stem cells into the blood. After reinfusion, growth factors are generally 
given again, to boost recovery.
These recent clinical advances are an invaluable advantage for the patient, but 
the problem of developing selectively toxic anti-cancer agents remains.
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DRUG DESIGN
The past century has witnessed the virtual realisation of one of man's ancient 
dreams - the conquest of disease through the use of effective drugs. Much of 
the drama of these discoveries arose from the opportunistic exploitation of 
unexpected observations, that combination of chance and sagacity known as 
serendipity. Recently, however, major new drugs have been developed 
through the application of scientific thought.
In 1940 Charles Huggins6 was responsible for the first ever demonstration of a 
synthetic drug having induced an unquestionable improvement in a malignant 
disease. As a professor of surgery at the University of Chicago, Huggins had 
been collecting prostatic fluid from dogs for several weeks as part of an 
enquiry into the effect of testosterone injections on prostatic fluid production. 
It was during one such study that he noticed that castration consistently caused 
regression of tumours which had spontaneously arisen in elderly dogs. 
Realising these tumours were hormone dependent, he then administered 
stilboestrol, a synthetic hormone with high oestrogenic potency, to produce 
'chemical' castration. His success encouraged him to conduct a successful 
clinical trial in patients with prostatic cancer which had spread into their 
bones.
These pioneering investigations were later confirmed by others and Charles 
Higgins was awarded the Nobel prize in 1966 for physiology and medicine.
More recent advances have been made using a more rational approach to drug 
design. The work described in this thesis attempts to adopt this approach.
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INHIBITION OF SIGNAL TRANSDUCTION ENZYMES
The aim of this project was to design, synthesise and test various structural 
analogues of the fungal metabolites which have been shown to have 
phospholipase D inhibitory capacity. This enzyme is critical to signal 
transduction in cells and its activation is a key step in the chain of events 
leading to cell division. The project presents a novel mechanism of action of a 
potential anti-neoplastic agent in the form of a signal transduction enzyme 
inhibitor and represents a rational approach to drug design.
The majority of currently available cytotoxic agents interact with DNA as 
their principal molecular source of action. Their general toxicity, as well as a 
feeling that clinical activity of these agents has reached a plateau has impelled 
cancer pharmacologists to consider novel targets for anti-cancer drug 
development7*8.
The stimulation of cell proliferation by growth factors involves a series of 
biochemical events which are regulated by the generation of intracellular 
messengers in response to the binding of the mitogen to the cell surface 
receptor. The signals implicated in the onset of mitogenesis are tyrosine 
kinase activity and changes in the levels of the second messengers cyclic 
AMP, DAG and inositol triphosphate. Transformation of cells by a number of 
oncogenes has been shown to subvert the regulation of pathways controlling 
second messenger concentration. Thus it is critical to the inhibition of the 
growth of both normal and a range of transformed cell types to identify key 
sites of regulation of these pathways which might serve as targets for 
therapeutic intervention9.
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THE PHOSPHOINOSITIDE CASCADE
The phosphoinositide cascade evokes a wide variety of responses in many 
kinds of cells10. Like the adenylate cyclase cascade, it converts extracellular 
signals into intracellular ones. The intracellular messengers formed by 
activation of this pathway arise from phosphatidyl inositol 4,5-biphosphate 
(PIP2 ), a phospholipid in the plasma membrane. PIP2 is formed by the 
phosphorylation of phosphatidyl inositol (PI), a membrane constituent 
synthesised from CDP-glycerol and inositol (see Fig. 1).
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FIGURE 1. Synthesis and receptor triggered hydrolysis of phosphatidyl 
inositol-4,5-biphosphate (PIP2).
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The binding of a hormone such as serotonin to a cell surface receptor leads to 
the activation of phosphoinositidase (or phospholipase C). This membrane- 
bound enzyme hydrolyses the phosphodiester bond linking the phosphorylated 
inositol unit to the acylated glycerol moiety. Two messengers, inositol 1,4,5- 
triphosphate (IP3) and diacylglycerol are formed by the cleavage of PIP2 . 
This hydrolysis is markedly stimulated by hydrolysis resistant analogues of 
GTP and by AIF4-, suggesting that a G-protein carries the excitation signal 
from the activated receptor to phosphoinositidase. The inhibition of this 
cascade by pertussis toxin also points to the participation of a G-protein.
IP3 is a short lived messenger, lasting only a few seconds. It can be converted 
to inositol by the sequential action of three phosphatases. The removal of the 
5-phosphate group terminates its messenger role. Inositol 1,4-biphosphate is 
hydrolysed to inositol 4-phosphate and then to inositol. Alternatively, IP3 can 
be phosphorylated to inositol 1,3,4,5-tetrakisphosphate, which is then 
hydrolysed to inositol 1,3,4-triphosphate, a different isomer from the one 
formed by cleavage of PIP2 . This 1,3,4-isomer can then be converted to 
inositol by successive dephosphorylations. The phosphatase that acts on 
inositol 1,3,4-phosphate is inhibited by millimolar concentrations of lithium 
ions. It is interesting to note that lithium is used to treat manic-depressive 
orders; it may exert its action by inhibiting the recycling of 1,3,4,- 
triphosphate. Some of the compounds formed in the conversion of IP3 to 
inositol may have messenger roles.
The action of IP3 has been investigated by microinjecting it into cells or by 
adding it to cells whose plasma membrane has already been made permeable. 
It has been found11 that IP3 causes rapid release of calcium from intracellular 
stores- the endoplasmic reticulum and, in smooth muscle cells, the
16
sarcoplasmic reticulum. The elevated level of calcium ions in the cytosol the 
triggers processes such as smooth muscle contraction, glycogen breakdown, 
and exocytosis. Indeed, the injection of IP3 into Xenopus oocytes suffices to 
activate many of the early events of fertilisation. Submicromolar levels of IP3 
mobilise calcium ions from intracellular stores by directly opening calcium 
channels in the membrane of the endoplasmic and sarcoplasmic reticulum.
For the purposes of this study, however, we are more interested in 
diacylglycerol (DAG), the other messenger formed by the receptor triggered 
hydrolysis of PIP2  and which activates protein kinase C (PKC). This 77kD 
enzyme phosphorylates serine and threonine residues in many target 
proteins^. For example, the phosphorylation of glycogen synthase by protein 
kinase C stops the synthesis of glycogen. This action of PKC nicely 
complements the IP3 -induced increase in the activity of glycogen 
phosphorylase which is mediated by an increase in the cytosolic level of 
calcium ions. Indeed, most effects of DAG and IP3 are synergistic.
The phosphorylation of proteins has long been recognised as a pivotal step in 
the generation and transduction of signals in the cell10. Protein kinases, the 
enzymes which catalyse protein phosphorylations and their complementary 
protein phosphatases are able to modulate the biological activity of proteins in 
a rapid and reversible manner12. With the advent of molecular cloning 
techniques the number of proven or putative receptors has risen, and the 
finding that a large number of receptors of growth factors and products of 
oncogenes are protein kinases underlines the important role that protein 
phosphorylation plays in the cell.
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One of the protein kinases, protein kinase C (PKC), is known to have a crucial 
influence on cell proliferation and differentiation13. Research interest in PKC 
has been stimulated by the finding that the enzyme is a cellular receptor 
through which the tumour promoting phorbol esters such as 12-0 - 
tetradecanoyl-13-acetate (TPA) mediate their pleiotropic effect on cells14*15.
It has been shown that PKC is only active in the presence of calcium ions and 
phosphatidyl serine16. DAG greatly increases the affinity of PKC for calcium 
ions and thereby renders it active at physiological concentrations of this ion. 
The inactive enzyme is located mainly in the cytosol, whereas the active form 
is membrane-bound.
DAG can be phosphorylated to phosphatidic acid, which reacts with CTP to 
form CDP-diacylglycerol. Alternatively, it can be hydrolysed to glycerol and 
its constituent fatty acids. Arachidonate, the C2 0_polyun saturated fatty acid 
that usually occupies the 2-position of the glyceryl moiety of PIP2 , is the 
precursor of a series of eicosanoid hormones, thus the phosphoinositide 
cascade gives rise to many molecules that have signalling roles17*18.
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PKC ACTIVATORS
Protein kinase C (PKC) has been referred to as the Clapham Junction of 
cellular signalling traffic19. It is widely distributed in the tissues and organs of 
mammals and other organisms. The purified protein consists of a single 
polypeptide chain with a molecular weight of around 77kD19 and is composed 
of two separate domains. The enzyme can be cleaved by calpain, a calcium 
dependent protease, to produce two fragments with molecular weights of 51 
and 26kD. The larger fragment is hydrophilic and contains the catalytic 
domain but is active in the presence of calcium, phospholipid, and DAG, 
while the smaller hydrophobic domain possesses the regulatory and membrane 
binding functions.
The enzymatic reaction catalysed by PKC is the transfer of the -phosphate 
group of ATP to seryl and threonyl, but not tyrosyl, residues of proteins. 
Activated by DAG, PKC is the site of action for tumour promoting phorbol 
esters15, of which TPA is the most potent. PKC phosphorylates many proteins 
including the EGF receptor, the insulin receptor and raspll.
Molecular cloning studies have revealed that PKC is in fact a family of 
enzymes of which several isoforms have been described, thus it seems feasible 
that the variety of PKC mediated cellular processes might be regulated by the 
differential expression of PKC isoforms. As an important integrator in signal 
transduction PKC is an especially attractive target for drug development.
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Activation of protein kinase C seems to be absolutely essential for mitosis20. 
Protein kinase C activity can be down regulated in some cell lines by chronic 
exposure to the tumour promoter TPA. The consequence of this is that the cell 
is unable to enter mitosis in response to growth factor stimulation and is also 
unable to divide in response to transfection by v-Ha-ras. Consequently 
inhibition of C-kinase activity has been regarded as a key site for therapeutic 
intervention of tumour states. However, despite some 10 years effort, no 
specific inhibitor has been developed. Protein kinase C is activated 
physiologically by DAG and is also the site of action of tumour promoting 
phorbol esters.
The importance of PKC in controlling cell division and proliferation is 
revealed by the action of the phorbol esters. These polycyclic alcohol 
derivatives from croton oil are carcinogenic; they are known tumour 
promoters. Phorbol esters activate PKC because they resemble DAG. The 
activation is persistent because, unlike DAG, they are not degraded.
A number of naturally occurring terpenoid compounds structurally unrelated 
to phorbol esters can activate PKC, e.g. mezerein, teleocidin, asplysiatoxin 
and ingenol 3-tetradecanoate, act as tumour promoters, mimic some of the 
other biological actions of these esters and compete with tritiated phorbol 
dibutyrate for binding to the phorbol ester receptor. In general the biological 
potency of the esters is paralleled by their PKC-activating activity. The 
propensity of phorbol esters to activate PKC is governed by a strict structure 
activity relationship. Computer molecular modelling of phorbol esters, related 
tumour promoters and DAG has shown a marked similarity in the relative 
position in space of certain heteroatoms and hydrophobic groups in these 
molecules21 »22»23.
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For phorbol esters, the pharmacophoric moieties are the hydroxyl groups at 
C4, C9 and C20 (see Fig. 2) and the hydrophobic region filled by a long chain 
acyl functionality attached to either the C12 or C13 positions. DAGs also fit 
this model in a stereospecific fashion therefore one might expect that 
exogenously added synthetic DAGs induce the same biological responses 
observed with phorbol esters.
Certain studies support this hypothesis, although some studies show a slight 
discrepancy in results possibly due to the fact that DAGs are much weaker 
activators of PKC than phorbol esters since they possess a much lower affinity 
for the enzyme and unlike phorbol esters are metabolised rapidly by kinases 
and lipases which renders DAG-mediated activation transitory.
All DAGs able to bind to and activate PKC in vitro have a 1,2-sn 
configuration, and neither the sn-2,3-DAG enantiomer nor the 1,3-DAG
(CH2)12CH3
2qCH2OH
FIGURE 2 - A Phorbol Ester (TPA).
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diastereomer are active8. The observed stereospecificity was also observed in 
intact cells, suggesting that a highly specific DAG-protein interaction is 
necessary for the activation of PKC.
Structure activity studies have shown that virtually any modification of the 
glycerol backbone of DAG results in a strong decrease in activity23. Examples 
of such modifications are the addition of a single carbon atom in the glycerol 
backbone or modifications of the hydrophilic residues of the DAG.
The structures of those compounds which inhibit PKC are seemingly as 
diverse as those exhibited by PKC activators23. Agents with PKC inhibiting 
properties have been found among ether phospholipids, dialkyl and 
alkylacylglycerols, lipoidal amines and an array of heterocyclic compounds 
such as aminoacridines, staurosporine and sangivamycin. In general these 
kinase inhibitors are neither selective for PKC nor are they, with the exception 
of staurosporine and certain related microbial products, very potent inhibitors. 
The mechanisms by which they inhibit PKC activity are manifold and are not 
completely understood.
It was originally thought that the source of agonist stimulated DAG was the 
phospholipase C-catalysed breakdown of PIP2 , however it is now clear that 
this only provides a minor component of the elevation in this second 
messenger system in response to mitogen stimulation in a range of cell 
types24, e.g. fibroblasts, smooth muscle cells and neutrophils. The major and 
sustained source of DAG ( and indeed that generated in response to mitogens 
that do not stimulate PIP2 breakdown e.g. EGF), is PC24 (see Fig. 3).
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FIGURE 3 - The phospholipase D pathway
Stimulated PC breakdown has been observed in a number of cell types in 
response to a range of mitogens, i.e. bombesin, vasopressin, prostaglandin F2 
alpha, PDGF, EGF, thrombin, endothelin and serum18. It has also been 
observed in response to stimulation with tetraphorbol acetate (TPA). In 
contrast to the breakdown of PIP2 , PC hydrolysis is catalysed by a 
phospholipase D type enzyme. The lipid product of this reaction is 
phosphatidic acid (PA). PA has been demonstrated to be mitogenic in its own 
right, but it can be converted to DAG by the action of phosphatidate 
phosphohydrolase. The regulation of PLD activity appears to be accomplished 
in both a receptor-dependent and independent manner25.
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Phosphatidylcholine (PC) is found almost exclusively in eukaryotic cell 
membranes and can account for up to 50% of the total cellular phospholipid 
content10.
PC from mammalian tissues normally contains a saturated fatty acid residue at 
the Cl position and an unsaturated fatty acid residue at the C2 position of the 
glyceryl moiety. Different species of PC have varying proportions of fatty 
acids e.g. stearic, arachidonic, linoleic, oleic thus phosphosphodiesteric 
cleavage of PC can lead to multiple species of DAG with important 
ramifications in cell activation. The fact that PC is a widespread receptor- 
linked process suggests that its importance in signal transduction is critical.
In addition to being activated by a diverse range of growth factors, an increase 
in PC breakdown has been shown in cells transfected by ras and src 
oncogenes. This raises the possibility that PLD is a convergent point in the 
action of both growth factors and certain oncogenes and therefore 
pharmacological intervention at the level of PLD may lead to the inhibition of 
the proliferation of both normal and cells transformed by a range of 
oncogenes. Consequently the identification of inhibitors of PLD may lead to 
the generation of novel, specific anti-cancer drug.
Although phospholipase D (PLD) activities of plant origin have been known 
since 1948, the existence of mammalian PLD acting on PC was first detected 
in 1975 using a microsomal preparation of the brain10. Subsequent studies 
have demonstrated PC-preferring PLD in homogenates and membranes from 
various tissues and cells including lung, liver, adipose tissue, epithelial cells, 
HL-60 cells and spermatozoa, with lung and brain being the richest sources. 
Mammalian PLD from various systems exhibits a transphosphatidylation
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activity. Requirements of calcium, fatty acids and detergents for PLD 
expression vary from cell to cell, suggesting again that multiple forms exist.
It has been demonstrated that growth factors can stimulate PC breakdown 
through activation of PLD. This conclusion can be derived from a range of 
studies demonstrating the appearance of [^H-choline] labelled cells before any 
choline phosphate is detectable. Since cells contain high levels of choline 
kinase and the resting level of choline phosphate in equilibrium labelled cells 
is 506 times higher than that of choline, it is likely that the rise in choline 
phosphate is due to the phosphorylation of the liberated choline (i.e. from 
choline hydrolysis) rather than a PLC activity being stimulated.
The most conclusive demonstration of agonist stimulated PLD activity has 
been by Pai et a l26. This group labelled HL-60 cells with an alkyl-[-^P] iySo- 
PC, which was incorporated into the membrane of these cells and rapidly 
acetylated. They then demonstrated that stimulation with N-formyl-Met-Leu- 
Phe caused the generation of alkyl-[32p] p a . Since the cellular pool of ATP is 
not labelled under these conditions, the alkyl-[32p] p a  must be formed 
through PLD catalysed hydrolysis of alkyl-[32p] PC.
The lead compound for this study is the compound viridin, a fungal 
metabolite from Trichoderma viride27 which has potent cytotoxic activity, at 
first thought to be through inhibition of PLD. It is now thought, however, that 
its activity may be mediated through an as yet undefined tyrosine kinase 
which may or may not have a direct action on levels of PLD in cells. Although 
it is not clear at which point in the second messenger system these compounds
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are acting, it is obvious that they are potent and structurally novel compounds, 
and a potential lead into a new generation of effective anti-cancer drugs.
This project has therefore involved:
1. the growth, isolation, purification and characterisation of the fungal 
metabolite viridin using a modified version of known techniques;
2 . identification of all structurally similar compounds using the search 
facilities by computer of the Crystallographic database CSSR;
3. determination of the crystal structure of demethoxyviridin;
4. partial synthesis of hibiscone C, a partial analogue of viridin;
5. similarity modelling of all compounds using HYDRA and MMS;
6 . building a QSAR model of previously synthesised analogues of wortmannin 
with known anti-inflammatory activity data;
7. correlating this model with synthesised analogues of demethoxyviridin to 
predict activity of new compounds;
8 . testing new compounds for cytotoxic and PLD/tyrosine kinase inhibitory 
activity;
9 . using these results to predict which compound will be the most active, 
hence which should be synthesised next;
10. synthetically modifying the most active analogue in order to optimise 
stability and other pharmacochemical properties such as lipophilicity.
CHAPTER 2
POSSIBLE ENZYME 
INHIBITORS
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LEAD COMPOUNDS
In neutrophils the respiratory burst induced by /-met-leu-phe, a chemotactic 
peptide, was shown to be dependent on PLD activation28 . The main 
consequence of phagocytosis in granulocytes and mononuclear phagocytes is 
this sudden, large increase in non-mitochondrial oxygen consumption 
commonly called the respiratory burst. In this process, oxygen is reduced to 
superoxide by an oxidase located in the plasma membrane while cytosolic 
NADPH is oxidised. The nature of the respiratory burst is still unknown. A 
flavoprotein and a b-type cytochrome were proposed as the components of 
what could function as an electron transport acceptor with oxygen as the final 
acceptor.
The triggering of the phagocyte by particles depends on the interaction of 
opsonic molecules and other surface determinants with plasma membrane 
receptors. The transduction sequence leading to the activation of NADPH 
oxidase is likely to involve an enhancement of cytosolic calcium, the 
breakdown of inositol phospholipids with generation of inositol triphosphate 
and DAG, and activation of PKC.
This respiratory burst is inhibited by the fungal metabolite wortmannin29, 
produced by Penicillium dangeardii.. This compound is a structural relation of 
viridin, produced by Trichoderma viride 30 (see Fig. 4).
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FIGURE 4 - Lead compounds
PLD activity can be readily quantified in intact cells by measuring the 
formation of phosphatidylalcohols, which are produced in a unique PLD- 
dependent transphosphatidylation reaction. Recent work by Wellcome 
Research Laboratories has indicated that in cytochalasin B-primed 
neutrophils, superoxide production stimulated by /-met-leu-phe, is totally 
dependent on PLD activation28. Wellcome have also shown that
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demethoxyviridin and wortmannin block phospholipase C and D activation in 
the human neutrophil25. Consequently, a modified viridin molecule (see Fig. 
4) was synthesised, tested and found to have inhibited PLD activity in 
neutrophils, Swiss 3T3 and NIH 3T3 cells.
O
OH
HO,
FIGURE 5 - A modified viridin structure [4].
Addition of this analogue to the medium of the cells inhibited the 
incorporation of [^H]- thymidine into the DNA of both control and 
transformed cells. There was no effect of the compound on agonist stimulated 
PIP2 hydrolysis and it appeared to have no effect on cellular morphology over 
the 24 hour period examined. These results suggest that PLD activity is 
essential for proliferation and that its inhibition by these compounds can 
prevent the growth of normal and transformed cells.
This was therefore the basis of the project to design a novel anti-cancer agent. 
A wortmannin or viridin derivative with maximum PLD inhibitory activity 
was sought to have optimum physicochemical features such as stability, and 
lipophilicity. These compounds were shown to have a preferential activity on
30
malignant dividing cells suggesting a desired selectivity of action may be 
present.
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MYCOLOGY
The two main lead compounds viridin and wortmannin are metabolites of 
the fungi Trichoderma viride and Penicillium dangeardii respectively.
EXPERIMENTAL
VIRIDIN
Trichoderma viride was obtained from Kew Mycological Institute in London 
as a freeze dried culture in test tubes. These were used to inoculate seed tubes 
that were then stored for 7 days at 25°C. A water suspension was produced by 
adding a few ml of water to each seed tube and gently scraping to rub spores 
from the growing fungus into the suspension. The solutions were bulked, 
homogenised and used to inoculate Roux bottles containing Raulin-Thom 
medium31 with extra tartaric acid added as in the literature method. The 
ingredients of this medium are shown below. The resulting suspension was 
green and soup-like.
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Deionised water h 2o 51
Glucose CH2OH(CHOH)4CHO 250g
Tartaric acid (CHOHCOOH)2 13.3g
Ammonium tartrate (CHOH.COONH4)2 13.3g
Di-ammonium hydrogen 
orthophosphate
(NH4)2HP04 2 .0g
Potassium carbonate k 2c o 3 2 .0g
Magnesium carbonate MgC03 1.35g
0.85g
Ammonium sulphate (NH4)2S04
0.25g
Zinc sulphate ZnS0 4 .7H20 0.45g
Ferrous sulphate FeS04 .7H20 0.45g
TABLE 1 - Raulin Thom medium.
This process was carried out under as sterile conditions as possible. These, 
along with two media control bottles, were then stored in the dark. These 
conditions were chosen after a trial batch was grown in the dark after this fact 
being mentioned but not explained in the literature, resulting in an increase in 
viridin yield from 23mg/l to 85mg/l with an increased purity of 91% 
compared to 65% when grown in the light. The pH was monitored daily. The 
fungus was cropped off after 21 days and extracted continuously with ethyl 
acetate. The pH at time = zero, and of the control bottles throughout the 
experiment was 2.9. The pH of the inoculated broth, however, fell gradually to 
a resulting value of 2.60.
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The purified extract yield from the broth varied from batch to batch but was 
usually around 80mg/l. In the initial stages of this project the mycelium, left 
after filtering, was dried and subjected to continuous soxhlet extraction, but 
this gave no compounds of sufficient interest. The concentrated crude extract 
was purified by chromatography as follows:
One lm silica plate was prepared for each 500mg crude sample. 50g of silica 
(GF2 5 4 ) was made into a slurry with approximately 200ml deionised water. 
This was then spread onto lm glass plates and the concentrated sample 
painted onto the dried plate in layers. The plates were immersed in a solvent 
tank containing 70:30 light petrol:ethyl acetate, the solvent ratios being 
previously determined by TLC. The plates were run once and the appropriate 
bands scraped off and washed several times with ethyl acetate. Viridin (Rf= 
0.47) was positively identified by melting point (222-224°C), high field NMR 
and mass spectrometry32 (for experimental data see Appendix 5). Its purity 
was later determined by HPLC. The literature also revealed that 6-viridin (Rf= 
0.36) could be separated from pure viridin. This was done by chromatography 
on a small silica plate with 10:1 toluene:methanol as solvent. 6 -viridin was 
positively identified by NMR: and melting point (140°C.).
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WORTMANNIN
The first few batches of Penicilliwn dangeardii received from Kew were 
discovered to be contaminated. The fungus was eventually isolated and grown 
under similar conditions as Trichoderma viride . The growth was bright 
yellow and the texture was of rubber when scraping the seed tubes for scaling 
up and inoculation into larger batches. When isolated, however, the main 
compound was produced in extremely low yield and did not give convincing 
TLC, NMR or mass spectrometry results. After several unsuccessful attempts 
to rectify this, a sample of wortmannin was donated by Sandoz for analysis at 
the Beatson Institute by HPLC.
DEMETHOXYVIRIDIN
The viridin samples initially isolated and purified were used for initial testing. 
As the results looked promising, more compound was required for analogue 
synthesis. SmithKline Beecham kindly donated a large sample of 
demethoxyviridin, which enabled several analogues to be made and tested. 
The demethoxyviridin comes from the fungus Nodulisporum hinnuleum.
HPLC ANALYSIS
HPLC analysis of viridin, wortmannin and B-viridin (see Fig. 4) was carried 
out at the Cancer Research Campaign Beatson Laboratories, CRC Department
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of Medical Oncology, University of Glasgow. Separate reverse phase HPLC 
assays were developed for the analysis of wortmannin and its breakdown 
products. Both assays used a C18 pBondpack column (5pm x 25pm) and a 
photodiode array detector at 200-500nm. For wortmannin, the mobile phase 
was methanol: acetonitrile: water (1:1:2), pH7, flow rate of lml/minute. For 
the breakdown products the mobile phase consists of methanol: acetonitrile: 
0.01M sodium acetate (1:1:2) at pH4. Fig. 6 shows resulting HPLC traces of 
wortmannin before and after 20  minutes had elapsed.
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FIGURE 6 - HPLC analysis of wortmannin.
Above -wortmannin, below - no wortmannin is seen after 20 minutes, some 
traces of degradation products are seen.
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PEAK %AREA 
t=0 minutes
%AREA 
t=20  minutes
1 3.04 3.84
2 (solvent peak) 62.44 88.95
3 1.21 6.17
4 (breakdown product) 1.53 1.04
5 (wortmannin) 31.77 -
TABLE 2 - Results from HPLC analysis of wortmannin.
Wortmannin was seen to degrade extremely rapidly, after 20 minutes there 
was no measurable peak 5. Peak 4, however, increased several times in area 
and was thought to be the major breakdown product. More of the substance 
represented by peak 3 was also seen, this was thought perhaps to be a minor 
degradation product. These breakdown products have been observed, unlike 
the parent compound, to show strong absorption at 440nm. This was used as 
the basis for an assay of the increase in degradation of wortmannin with time 
to determine half-life (see Fig. 7).
At physiological pH, wortmannin was found to degrade rapidly and 
completely with a half life of less than 10 minutes (figure 7). The breakdown 
of wortmannin is a pH dependent process since degradation can be prevented 
by acidifying aqueous solutions of the molecule (pH5). For cytotoxicity assays 
where dilutions are made at pH 7.4, wortmannin has been shown to be fully 
degraded by the time the drug is added to the cells. The breakdown product of 
wortmannin may therefore be crucial in the activity, and our understanding of 
the cytotoxic activity, of these compounds.
38
Unfortunately, sample size was not sufficient to allow isolation and analysis 
of these products.
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FIGURE 7 - Decomposition of wortmannin shown by increase in breakdown
products.
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Cytotoxicity studies have been carried out by co-workers at the Beatson 
Institute in Glasgow. It was found that wortmannin is cytotoxic to Swiss 3T3 
cells with an ID50  of 41.3 ±1.9 |iM and inhibits phospholipase D (figure 8). 
The inhibition of phospholipase D was measured by co-workers in the 
Biochemistry department at Glasgow. This test was based on a 
transphosphatidylation assay. It is known that PLD catalyses the cleavage of 
the terminal diester bond of phospholipases (see Fig.9). It's preferred substrate 
is phosphatidylcholine, thus generating phosphatidic acid (PA) and choline 
(Cho). PA will then be hydrolysed by phosphatidic acid phosphohydrolase, 
and break down to generate diacylglycerol. If cells are labelled with 
[3H]palmitic acid, which is taken up by the cells as R.2 of the PC, then 
stimulated in the presence of butanol, a butylated adduct is preferentially 
formed which cannot be hydrolysed by the PA specific enzymes, and can then 
therefore be counted by scintillation counting after extraction (see Fig. 10).
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FIGURE 8 - Inhibition of phospholipase D by wortmannin
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R1 Phosphatidylcholine PC
FIGURE 9 - Hydrolysis of phosphatidylcholine by PLD.
Rl= usually saturated fatty acid, R2 = *palmitic acid
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FIGURE 10 - PLD assay.
Demethoxyviridin showed significant cytotoxity against a panel of cell lines 
including Swiss 3T3s, mink cell lines, ovarian and breast tumour cell lines 
(table 3)34. It appeared to be most toxic to ovarian tumour cells. B-viridin was 
also later tested in Swiss 3T3s and found to be several times more active than 
viridin (see Fig. 11). After 5 days in a l|im  solution of inhibitor, B-viridin 
showed 7 x 10"^ cells remaining whereas viridin showed in the order of 10 x 
10‘4 Thus B-viridin was a more potent inhibitor of cell growth.
Cell lines Demethoxyviridin DD5o(|im)
Swiss 3T3 34.0±1.2
Mink type I 114.0±1.0
Mink type II 130.0±6.0
Mink type III 142.7±3.0
Mink type IV 113.7±2.0
Ovarian tumour type I 20.5±0.5
Ovarian tumour type II 32.010.6
Ovarian tumour type III 26.810.4
Breast tumour 123.319.0
TABLE 3- Cytotoxicity data for demethoxyviridin.
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FIGURE 11 - Inhibition stimulated cell growth by B-viridin. 
Bombesin = mitogen 
FCS = foetal calf serum, growing medium for cells
45
Figure 12 shows results of the viridin light study where it was shown that 
growing the fungus in the dark increases the viridin yield and purity. The first 
peak is thought to be B-viridin.
It was seen that the viridin extracted from the fungus grown in the light had 
about 32% impurity, thought to be B-viridin. From the dark sample, however, 
the B-viridin content was only 9% (see Table 4). B-viridin was later tested and 
found to several times more active than viridin (see later). Although the 
percentage B-viridin was higher when the fungus was grown in the light, the 
combined sample extracted was much greater from the dark. It was therefore 
decided not to change the extraction conditions at this stage.
PEAK LIGHT DARK
1 (B-viridin.):
AREA 0.555 0.127
% 32.18 9.05
2 (viridin.)
AREA 1.060 1.275
% 61.48 90.62
TABLE 4 - HPLC analysis results of viridin light study.
B-VIRIDIN VIRIDIN
B-VIRIDIN VIRIDIN
FIGURE 12 - HPLC analysis of viridin light study.
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STRUCTURALLY RELATED COMPOUNDS
The Chemical Databank System (CDS) at Daresbury Laboratory provides a 
reliable service for the retrieval of chemical data, the graphical display of 
structures and the analysis of numerical data.
A retrieval system written at Daresbury provides a common method of access 
to a number of databanks and has a number of special features e.g. fast 
chemical structure retrieval facilities. The local software supports chemical 
connectivity searching facilities for five of the databases. The performance of 
this system depends on the pre-processing of data to produce structured 
indexed files. The service can be used form any terminal which can be 
connected to JANET, the Joint Academic Network. One of the databanks 
which can be accessed in this way is CSSR (Crystal Structure Search 
Retrieval), the Cambridge Structural Databank, which contains crystal 
structure data for about 90,000 organic and organo-metallic compounds. The 
program runs at Daresbury and provides fast retrieval of structural and 
bibliograhic information on the VAX computer at Glasgow, allows logical 
manipulation of retrieved material, and display of results. Using an 
appropriate graphics terminal and the associated program VIEW, labelled 
stick diagrams or stereo-pairs of molecules can be displayed. These may be 
scaled or rotated, and bond length and angle calculations made.
An important feature of this program is its ability to use molecular fragments 
designed by the user in order to search for structures which contain these 
fragments or certain characteristics of them. A query structure is an
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arrangement of atoms and bonds which is stored as a connection table which 
specifies how the atoms are connected. This table may be displayed as a 
conventional chemical diagram.
Using this program, the query structure in figure 13 was designed as a 
representation of the key chemical features of viridin and wortmannin. The 
crystal structures of viridin34 and wortmannin35 had been previously 
determined.
O
FIGURE 13- Query structure [5] used to search Cambridge database.
This structure was used to search all the compounds in the database. Similar 
compounds of interest are shown in figure 14 :
Halenaquinone - a pentacyclic polyketide isolated from a marine sponge 
Xestospongia exigua, first collected in Palau in the Western Caroline 
islands36.
Demethoxyviridiol - a metabolite of the fungus Nodulisporum hinnuleum. 37
Hibiscone C - an extract from the Blue Mahoe, Hibiscus elatus, the national 
tree of Jamaica38.
1. Halenaquinone [6 ]
OH
HO
2. Demethoxyviridiol [7]
3. Hibiscone C [8 ]
FIGURE 14 - Structural analogues found from CSSR search.
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The co-ordinates of these compounds were stored in files and transferred to 
Glasgow via JANET. The co-ordinates of viridin had been published and 
those of wortmannin were requested and donated by Sandoz. The 
photosynthesis of hibiscone C had been documented and was carried out with 
a view to producing rigid structure analogues (see Chapter 5).
Further literature searching reyealed several similar compounds for which the 
crystal co-ordinates were not known (see figure 15):
V irone [9] - is produced by Trichoderma viride grown at a higher 
temperature than that which produces viridin39.
Viridiol [10] - a minor metabolite when the fungus is grown at the normal 
room temperature40’41.
Wortmannolone [11] - is produced by Penicillium dangeardii39. 
Demethoxyviridin [3] - produced by Nodulisporum hinnuleum 37.(see Fig.4)
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\  / CH3 C
1. Virone O
OH
HO
2. Viridiol 
[10]
HO
3. Wortmannolone 
[11]
FIGURE 15 - Virone, Viridiol and wortmannolone
Demethoxyviridin [3] was also donated by Wellcome and the crystal structure 
determined, (see Chapter 4).
CHAPTER 3 
COMPUTER MODELLING
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COMPUTER MODELLING
In studies of quantitative structure activity relationships (QSAR), the relative 
potencies of a series of drugs are subjected to analysis with the hope that 
biological potency will be described by a mathematical equation. QSAR is an 
actuarial or statistical method in which only objective data are used with no 
intrusion of models or mechanistic hypotheses. The equation that is obtained 
not only accounts for the relative potencies of the compounds, but from it are 
deduced predictions of the potencies of untested compounds. The method thus 
has the capability of yielding new (structurally related) drugs with desired 
potency, perhaps drugs with enhanced potency or fewer side effects.45 
Computers are also an invaluable aid to this method in terms of sheer 
magnitude of calculations and of visualisation of techniques and results on 
powerful graphics workstations.
In a series of structurally related compounds, some analogies seem to be 
traceable although there are always exceptions. For example, it is widely 
accepted that substitution of an aromatic ring by chlorine in a biologically 
active molecule 'deepens' activity.44 This has been explained by invoking the 
Hammet substitution of chlorine and the push-pull electron density changes 
brought about by the substitution. It may be, however, that the chlorine atom 
blocks aromatic hydroxylation and thereby prevents metabolic removal of the 
active species. Although such speculation anticipate more contemporary ideas 
of drug action, the problems existed 85 years ago and seemed to resist 
solution. In 1893 the French physiologist Charles Richet tried to formulate 
S AR mathematically44 but this procedure had to wait another six years when 
Hans Horst Meyer and E. Overton published studies in which narcotics were 
ranked according to their solubility in blood and lipids44 (i.e. water and 
organic solvent). These theories of a relationship between the physical
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properties of a compound and its biological properties were taken up by others 
and revived decisively by Corwin Hansch in 196444. The lipid theory was 
followed by ideas concerning other physical properties such as ionisation and 
a proposal by Linus Pauling that narcotics interfere with clathrate formation of 
ice crystals in the central nervous system and thereby prevent normal nervous 
transmission of pain impulses44. These proposals, whether right or wrong at 
the time, were but rare attempts to rationalise an increasingly unruly 
accumulation of therapeutic data that defied explanation.
The programs used to study viridin, wortmannin and their analogues in an 
attempt to elucidate structural information from them which could be 
correlated with biological potency were MMS45 (molecular modelling 
system), HYDRA46, ORTEP47, PYTHON48 and SYBYL.49
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MMS, HYDRA AND ORTEP
Files with the crystal co-ordinates for the structural analogues available were 
converted from fractional to orthogonal co-ordinates using a locally written 
converting program GX-PDB51. These were transferred to the UNIX system 
for use on the Silicon graphics IRIS computer. Using the program MMS 
(Molecular Modelling System), a template molecule file was prepared and 
atom labels matched to those of the co-ordinate file. The molecule could then 
be displayed and manipulated in real time on the terminal.
More than one molecule can be displayed at a time hence qualitative 
comparisons can be drawn. For example, the A and B rings of hibiscone were 
slightly buckled in the opposite direction to both viridin and wortmannin. 
Ring C of halenaquinone and viridin were also angled away from each other 
although rings A and B were more or less identical. Figure 16 shows viridin 
(yellow) and wortmannin (blue) face on and translated slightly from their 
docking positions. What cannot be seen from this angle, however, is shown in 
Figure 17 where the molecules are shown side on and are seen to curve in 
slightly different directions. This may account for slight changes in potency of 
enzyme inhibition due to molecular recognition at the enzyme site.
Some basic overlap experiments were carried out to assess molecular 
similarity between the compounds for which crystal structures were known, 
namely viridin, hibiscone C, demethoxyviridin and wortmannin. The co­
ordinates of the former two compounds were easily available in the literature, 
the crystal structure of demethoxyviridin was determined (see Chapter 4) and 
the co-ordinates of wortmannin were kindly donated by Sandoz of 
Switzerland on direct request. The atoms overlapped (Figure 18) in each 
compound were chosen because it has been shown that the unique ABE ring
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FIGURE 16 - Viridin (yellow) and wortmannin (blue) - face on and translated.
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FIGURE 17 - Viridin (yellow) and wortmannin (blue) - Side view.
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system is crucial for activity. The results of these experiments are shown in 
Table 5.
O
Figure 18 - Atoms overlapped and thought to be crucial for activity
Molecule 1 Molecule 2 Average
displacement
(A)
Max. displacement
(A)
Viridin Wortmannin 0.033 0.052
Viridin Demethoxyviridin 0.013 0.018
Viridin Hibiscone C 0.026 0.039
Wortmannin Viridin 0.033 0.052
Wortmannin Demethoxyviridin 0.024 0.044
Wortmannin Hibiscone C 0.053 0.104
Hibiscone C Viridin 0.026 0.039
Hibiscone C Wortmannin 0.053 0.104
Hibiscone C Demethoxyviridin - -
Demethoxyviridin Viridin 0.013 0.018
Demethoxyviridin Wortmannin 0.024 0.044
Demethoxyviridin Hibiscone C “ “
TABLE 5 - Results of overlap experiments
The average displacement is the average distance between corresponding 
atoms of molecule 1 and molecule 2 after overlapping according to the query 
structure in Figure 18. The maximum displacement is the greatest single
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distance between these corresponding atoms. Thus these measurements are a 
crude measure of structural similarity.
Presuming demethoxyviridin is most potent, from test results (see later) and 
that the furan ring system is indeed necessary for activity, from the 
wortmannin analogue study, the results from Table 5 would predict a 
decreasing order of potency:
Demethoxyviridin 
Viridin 
Hibiscone C 
Wortmannin
This assumes that the most structurally similar compound to the most active 
compound will be next in order of potency. Viridin is closest in structure to 
demethoxyviridin, as expected and seen from the results in Table 5, and 
hibiscone C is closer in structural distances than wortmannin to viridin.
Although activity data for the hibiscone C part structure analogue turned out 
to be disappointing, i.e. the compound was not at all active in the test systems 
used, demethoxyviridin was shown to be more active than viridin which in 
turn was more active than wortmannin.
Figure 19 shows an example of docked viridin and demethoxyviridin. It can 
be seen that although the two molecules are largely identical, when the ABE 
ring system is docked, rings C and D are slightly out of alignment. This 
difference in shape, in addition to the loss of a methoxy group, may account 
for the difference between the two molecules in activity at the receptor site.
FIGURE 19 - Overlap of viridin and demethoxyviridin.
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By loading an appropriate symmetry file, the molecules could be displayed as 
crystal packing diagrams (figure 20) where the regular zigzag arrangement of 
the structure can be seen, perhaps mimicking interactions taking place at the 
receptor site. The electron density of the molecule can also be generated by 
creating dot surfaces (figure 21 ) and space filling models (raster diagrams) 
(figure 22) can be depicted using the program HYDRA.
Using enlarged versions of crystal packing diagrams and distance calculations, 
possible hydrogen bonds could be identified between molecules in adjacent 
unit cells. These could be represented pictorially using a graphics terminal 
linked to the main VAX and the program ORTEP.
Figure 23 shows the unit cell of demethoxyviridin. The distances between 
atoms 0 (2 0 ’) and 0(24'), the hydroxyl and the carbonyl groups, was 
calculated to be 2-83A, indicative of possible hydrogen bonding between these 
two atoms. A distance of 2-83A was also calculated between 0(18') and 0(20) 
thus these molecules lie in a zigzag arrangement (seen in Figure 24) linked by 
two hydrogen bonds. This arrangement may be important as it may mimic the 
way in which the molecules approach the receptor site. Viridin, unit cell 
shown in Figure 25, is linked by a single hydrogen bond. The carbonyl groups 
of the AB rings do not seem to be involved in bonding in this molecule but a 
similar zigzag arrangement is seen (figure 26). There are no apparent 
hydrogen bonds in the unit cell of wortmannin (figure 27) and the combined 
unit cell arrangements show the molecules lining up in a pairwise manner 
(figure 28). Hibiscone, similarly, does not show any signs of obvious H- 
bonding (figure 29) but does show a slight zigzag pattern in the crystalline 
form (figure 30).
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FIGURE 20 - Crystal packing diagrams of viridin (above) and wortmannin
(below).
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FIGURE 21 - HYDRA generated Van der Waals surface display of viridin.
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FIGURE 22 - HYDRA generated raster display of vindin.
64
FIGURE 23 - Unit cell of demethoxyviridin.
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FIGURE 24 - Repeated unit cell o f demethoxyviridin.
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FIGURE 25 - Unit cell of viridin.
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FIGURE 26 - Repeated unit cells of viridin.
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FIGURE 27 - UnitrH imt cell o f  wortmannin.
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FIGURE 28 - Repeated unit cells of wortmannin.
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FIGURE 29 - Unit cell of hibiscone C.
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FIGURE 30 - Repeated unit cells of hibiscone C.
72
STATISTICAL METHODS IN QSAR
One of the most important considerations in QSAR studies is the statistical 
analysis of the correlation of the observed biological activity with structural 
parameters. The coefficients of these parameters that establish the correlation 
with the biological activity can be obtained by a regression analysis. Since the 
models are constructed in terms of multiple additive contributions, the method 
of solution is also called multiple linear regression51. This method is based on 
three requirements:
(i) the independent variable (structural parameters) are fixed variates and the 
dependent variable (biological activity) is randomly produced,
(ii) the dependent variable is normally and independently distributed for any 
set of independent variables,
(iii) the variance of the dependent variable must be the same for any set of 
independent variables.
The biological activity satisfies the second and third requirements, since each 
measurement is done independently. Upon repeated measurements the values 
will be normally distributed, and will have an equal variance. In the usual 
situation, m observed values are fitted to an equation with n variables and p 
parameters by a least squares procedure.
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This procedure defines the best fit by requiring that the sum of differences 
between the observed and the calculated values can be minimal. Goodness of 
fit can then be defined by three quantities:
(i) the multiple correlation coefficient, r,
(ii) the standard deviation of regression, s,
(iii) the overall test F value for the test of coefficient significance.
The correlation coefficient gives an indication of the correspondence of 
observed and calculated values. Its square, r 2, can be interpreted as the 
fraction of variance in the observed data which is explained by the correlation. 
The standard deviation of the regression is a measure of the scatter of the 
experimental values from the mean. The overall F value indicates how much 
better is the correlation (within a certain degree of significance level) from the 
correlation in which all the coefficients are taken as zero.
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PYTHON
Initial studies were done using the program PYTHON available from Oxford 
Molecular and data from a paper publishing results of anti-inflammatory data 
of a series of wortmannin analogues29. This paper describes how the measure 
of inhibition of the respiratory burst in cells can be used as a direct measure of 
the anti-inflammatory potency of a compound. The program was used in York 
as part of a molecular graphics course. A spreadsheet was prepared using 
initially seven of the wortmannin analogues (see figure 31).
The columns entered included the log of the given IC50  value (log A), 
indicator variables, Verloop values (i.e. a measure of the size and direction of 
each substituent), lipophilicity (II) -related to log P, the latter two values 
being calculated automatically by the program.
Several graphs were plotted. No direct correlation was seen with activity and 
Verloop values or initially with lipophilicity so two rows were excluded from 
the table as they were structurally more different than the others. These five 
points were plotted and analysis done yielding the equation:
y= 0.077xi + 1.059x2 + 0.913x3 + 1.855
where y = log activity
xi = indicator variable 1 
x2  = indicator variable 2 
X3 = II (lipophilicity)
(Indicator variable 1 was the presence of an acetoxy group on R\ and indicator 
variable 2 was the presence of a substituent other than H on R3.)
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Ha CO.
OO
OH
Molecule 1 [1] Rl=OAc r 2=o r 3=h R4=closed ring
Molecule 2 [12] Rl=OAc r2=o R3=OAc R4=closed ring
Molecule 3 [13] Rl=OAc r2=o r 3=h R4=NHC6H5
Molecule 4 [14] Rl=H r2=o r 3=h R4=closed ring
Molecule 5 [15] Rl=H r 2=o r 3=h R4=OH
Molecule 6 [16] Rl=OAc r 2=o h r 3=h R4=closed ring
Molecule 7 [17] Rl=H r 2=o h r 3=h R4=closed ring
Figure 31 - Seven wortmannin analogues whose known anti-inflammatory 
data is used in a initial model using the program PYTHON. Molecules 3 and 5 
were eventually discarded from the study due to significant structural 
differences i.e. the closed furan ring was seen to be critical for activity and a 
valid model.
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This equation gave an R value of 0.989 i.e. the r^ value was around 0.85 
which meant that 85% variance was explained by this equation. The F value 
was 14.85 with 3 degrees of freedom.
From this PYTHON model activities could be predicted (see Table 6).
MOLECULE ACTUAL PREDICTED
IC50 IC50
1 1.447 1.377
2 2.436 2.436
4 1.892 1.962
6 1.230 1.300
7 1.954 1.885
TABLE 6 - Predictions of activity from PYTHON results.
These initial results were very exciting in that they showed that a valid 
statistical model could be formed for this set of compounds and could possibly 
be used to predict the activities of as yet unsynthesised and untested 
compounds. Both the order and value of predicted potency were correct within 
statistical limits.
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SYBYL
The program PYTHON was only available during the course of a one week 
training seminar at York so the same theories were applied to the more 
sophisticated methodology and graphics equipment available at Glasgow. The 
program used was SYBYL by Tripos and the main methods used included 
CoMFA techniques and general QSAR methodology.
A major goal in chemical research is to predict the behaviour of new 
molecules, using relationships derived from analysis of the properties of 
previously tested molecules. Relationships derived primarily by empirical 
analysis of a data table, whose compounds are numerical property values and 
whose rows are compounds, usually taking the form of a linear equation, are 
called quantitative structure activity relationships (QSAR).
Especially in biological applications, it has long been agreed that the most 
relevant numerical property values would be shape dependent. Work on 
comparative molecular field analysis (CoMFA) began 12 years ago52 with two 
additional observations: (1) at the molecular level, the interactions which 
produce an observed biological effect are usually non-covalent; and (2) 
molecular mechanics force fields, most of which treat non-bonded covalent 
interactions only as steric and electrostatic forces, can account precisely for a 
great variety of observed molecular properties. Thus it seems reasonable that a 
suitable sampling of the steric and electrostatic fields surrounding a set of 
ligand or drug molecules might provide all the information necessary for 
understanding their biological properties. However, the emergence of a 
practical CoMFA methodology had to await a new method of data analysis, 
partial least squares (PLS), which can derive robust linear equations from
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tables having many more columns than rows and a number of advances in the 
methodology of molecular graphics.
One of the studies using CoMFA was published in 1992 by a group of 
workers at Sterling Winthrop in New York53 . They showed that the CoMFA 
analysis of eight compounds related to disoxaril for which X-ray structures of 
the molecule bound to HRV-14 had been determined resulted in a strong 
positive correlation of activity with steric effects of the compounds, 
particularly toward the pore end of the compound binding site, and no 
correlation with electrostatic effects. These results confirm what had been 
previously found, that the activity of these compounds was highly dependent 
upon their hydrophobic nature expressed as log P or lipophilicity. The 
CoMFA study also confirmed results from the comparison of a series of active 
and inactive compounds using volume maps which showed that bulk at the 
pore end of the molecule was conducive to high levels of antiviral activity 
while excessive bulk around the ring led to poor activity.
Other 3D QSAR methodologies have been described. The molecular shape 
(MS) approaches, developed independently by Simon et a /54>55 and by 
Hopfinger56, compare net rather than location-dependent, differences in 
molecular connectivities, volumes and/or fields. A second approach, the 
distance geometry method of Crippen57, provides validation of a site-point 
hypothesis, a list of binding set co-ordinates and properties that must be 
proposed by the investigator. In related work, for exploring binding modes of 
ligand to receptors, Goodford advocates the display of probe-interaction 
'grids', similar to those used in CoMFA58, while Hansch, Blaney, Langridge et 
al59 have shown the complementarity of QSAR and molecular graphics in 
understanding enzyme inhibitory data.
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CoMFA (Comparative Molecular Field Analysis) is a technique used only in 
the SYBYL program. It is a method which uses multivariate regression 
techniques to seek relationships between properties such as biological activity 
and various 3D structural features such as molecular shape and charge 
distribution.
Critical to a preparation of a CoMFA analysis is the building of a database of 
compounds similarly aligned and with their electron density and charge 
distribution calculated. Once minimised conformations of all the structures are 
in hand, the next step in the CoMFA process is to establish a mutual spatial 
alignment of the molecules within a series. This can be done by computing the 
fields associated with each of the molecules and then minimising the RMS 
differences between them by adjusting their positions (using the 'Field Fit’ 
technique in SYBYL). With the wortmannin and viridin structures, however, 
the structural similarity was such that the molecules were aligned carefully by 
hand, using a process that seemed more intuitive and overlapping the ABE 
fused ring system of each compound.
The non-bonded energy fields associated with any structure are determined in 
CoMFA by first placing the structure in a 3-D lattice and then computing the 
steric (Lennard Jones) and electrostatic interactions within the molecule that 
are experienced by a probe atom60 e.g. C+ at all of the lattice points around the 
molecule. A lattice grid spacing of 2 k  in the x, y and z directions was used. 
These data are built into a CoMFA table which has 1 row per 'standard' 
compound and hundreds or thousands of columns to carry all the CoMFA 
energy filed data. The statistical task at this stage is to establish by regression 
analysis over the whole set of compounds a relationship between these 
variables on the one hand, and the biological activity data on the other hand.
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The biological activity data were entered in the CoMFA table as 1/lnICso 
values.
Due to the very large number of independent variables in this system, the 
standard techniques of multiple regression cannot be applied directly and 
Partial Least Squares (PLS) analysis is employed to derive linear equations 
from the data. The quality of any model derived can be determined by a cross 
validation technique, sometimes referred to as the 'leave-one out' method. It 
measures the true predictive capability of a model by removing a subset 
('cross-validation group') of one or more structures from the set of standard 
compounds C the training set'), re-entering them as unknowns and predicting 
their activity. The sum of the squared differences between predicted and actual 
activities is compared to the standard deviation of the actual activities to yield 
a 'cross-validated r^' as a measure of predictivity. This value can range from 
negative numbers to a maximum of +1.0. A cross-validated r^ of above 0.4 is 
said to be statistically relevant and one of 1.0 corresponds to a perfect model, 
i.e. all predictions are 100% accurate. A value of 0 indicates that no statistical 
relationship exists between the CoMFA fields and the activities, and the 
predictions are no better than random numbers whose average is the mean of 
the measured activities. Negative values result from an inverse relationship 
between the actual and predicted activities and can be regarded as worse than 
no model at all.
In all cross-validation runs performed in the course of these studies, the 
number of cross-validation groups was chosen to equal the number of 
structures in the CoMFA table, i.e. the activity of each structure was predicted 
individually from all other structures. This guarantees reproducibility and 
comparability of subsequent cross-validation runs. The standard deviation 
threshold for exclusion of columns from the PLS analysis
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(MINIMUM_SIGMA) was set to 0.5 for cross-validation runs, and to 0.0 for 
the final non-crossvalidated analyses.
CoMFA models can be built using a number of components in the linear 
equation derived by the PLS analyses. This number corresponds to the level of 
detail at which the PLS analysis has been conducted on the molecular fields, 
and is analogous to the number of coefficients in conventional multiple 
regression. Up to n-1 components can be used, with n the number of structures 
in the CoMFA dataset. In the crossvalidation runs, a crossvalidated r^ value is 
calculated for each value n in the specified range of components (n = l...m, 
m< n-1). CoMFA QSAR models which allow the prediction of the activity of 
novel compounds are derived from (final) non-crossvalidated runs. For these 
models, one specific number of components had to be chosen. A number is 
usually chosen which is lower that the one yielding the highest cross-validated 
r^, since the number of components at which the usually steep initial increase 
of the crossvalidated r^ starts to level off has proven to yield better predictive 
CoMFA models. Higher numbers of components tend to ’overfit' the CoMFA 
model to irrelevant minutiae of the molecules in the dataset and may lead to 
less accurate predictions.
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SYBYL - EXPERIMENTAL
While no actual cytotoxicity test results were yet available, a model was 
formed using the wortmannin analogues previously synthesised. This was 
based on the assumption that anti-inflammatory data would be related in some 
way to cytotoxicity data, and also comparable initial test result data showing 
that both wortmannin and viridin had potent cytotoxic potential.
The wortmannin analogues were built in SYBYL and energy minimised. Each 
molecule was added to the same database. Del-re charges61 were calculated 
for each molecule which was then aligned by hand using the virtual dial 
system so that a good 3D alignment was easily possible. Each molecule was 
held in this orientation by the option FREEZE_VIEW and re-added to the 
database. A new spreadsheet was made and each molecule to be in the 
CoMFA study was added. From the menu option in this spreadsheet, the 
alignments of the molecules were defined by the command sequence CoMFA 
A L IG N M E N T  DEFIN E AS_IS MO LEC UL E_ N  AME 
MOLECULE_ALIGNMENT_NAME END. This defines each molecule to be 
critically aligned as the frozen conformation and allows the flexibility of 
different conformations if desired. The option AUTOCoMFA is then selected 
which automatically calculates the electrostatic and steric fields for each 
molecule, stores this information in the spreadsheet where it can be 
EXRACTed and analyses the results by multivariate analysis. A good initial 
estimate of whether the analysis is successful or not is the critical value of r2 
which should be greater than 0*4.
An initial study was carried out using a selected group of compounds ([1], 
[12], [13], [14], [16], [17]) which were reasonably structurally similar. These
83
were placed in a table and an automatic CoMFA run was carried out. The 
resulting electrostatic and steric map can be seen in Figure 32.
The r^ value for this analysis was 0.611. The relative contributions from each 
variable are shown in Table 7:
Norm. Coefficient Fraction (%)
1. Autocomfa (STERIC) 0.830 58.2
2. Autocomfa (ELECTROSTATIC) 0.597 41.8
TABLE 7 - Relative contributions from steric and electrostatic variables.
From the electrostatic map shown in blue and yellow (Fig. 32), the yellow 
regions represent areas where increased negative charge would lead to 
increased activity, and the blue regions represent regions where increased 
positive charge would lead to increased activity. The most strikingly apparent 
result from this study was the suggestion that a chemical group, e.g. 
containing a nitrogen or other atom which could easily protonate, substituted 
on the acetoxy group on ring C of wortmannin would lead to increased 
activity. The steric map is usually shown in red and green where the red 
regions represent areas where less bulk would lead to increased activity. In 
this case the green regions were more apparent, showing areas where 
increased bulk would lead to increased activity, in particular the acetoxy 
group mentioned above and the carbonyl substituent on ring D. Substitution at 
these two groups was therefore seen as a priority for the organic chemists 
working separately on this project, providing a clear lead to be assessed. 
Similar studies using molecules 1-10 with extremely careful alignment gave
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an r2 value of 0.624 (final non crossvalidated r2 = 0.957) (see later). The 
results of each study can be easily validated by a number of different 
techniques such as bootstrapping, crossvalidation, factor analysis and 
partial least squares.
85
FIGURE 32 - Electrostatic (blue and yellow) and steric (green) maps from
wortmannin CoMFA study.
Blue - increase positive charge 
Yellow - decrease positive charge 
Green - increase bulk
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BOOTSTRAPPING
In many SYBYL/QSAR analyses, confidence intervals (mean and standard 
deviation) for the parameters to be estimated can be calculated by a modem 
validation method, the bootstrap. The name is derived from the old saying 
about pulling yourself up by your own bootstraps. The idea is to simulate a 
statistical sampling procedure by assuming that the original data set is the true 
population and generating many new data sets from it. These new data sets 
(called bootstrap samplings) are of the same size as the original data and are 
obtained by randomly choosing samples or rows from the original data, where 
repeated selection of the same row is allowed. The statistical calculation is 
performed on each of these bootstrap samplings, new values being calculated 
for each of the parameters to be estimated. The difference between the 
parameters calculated from the original data set and the average of the 
parameters calculated from the bootstrap samplings is a measure of bias of the 
original calculation. The calculated variance of the parameter estimates the 
accuracy with which any of the parameters can be estimated from the input 
data. This process is shown in figure 3362.
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Original Random Selection
Table of Row-Compounds
Derive
^Model
Repeat many times
Save
Model
y = ax + by
Accumulate Means 
1 and Standard Deviations
y = Ax + By 
r =.. s =..
FIGURE 33 - The bootstrapping process
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CROSSVALIDATION
Crossvalidation is an approach for selecting which model, among several with 
different levels of complexity, is most likely to have predictive value. It is 
particularly useful in PLS (Partial Least Squares), to establish the number of 
components which optimally distinguish signal from noise.
In contrast with the classical statistical techniques such as the F-test, 
crossvalidation substitutes modem computational power for the theoretical 
assumptions about data distributions. Crossvalidation assesses the probable 
predictive power of a particular model by the brute force method of attempting 
predictions of all the input target data values.
As shown in figure 3423, crossvalidation proceeds by omitting one or more 
rows of input data, re-deriving the model, and predicting the target property 
values of the omitted rows. The rederivation-and-prediction cycle continues 
until all target property values have been predicted exactly once. The root 
mean square error of all target predictions, the press (predictive sum of 
squares), is the basis for evaluating the current model.
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Original Crossvalidation
Table Subtable
Derive Model
Excluded
Compound-Rows
Predict Biological 
Properties of 
Excluded 
Compound-Rows
Excluded
Biological
Properties
PredictedActual
Differences
Repeat 
until ALL 
Compound-Rows 
Predicted Once
Standard Deviation =
"PRESS"
FIGURE 34 - The crossvalidation process
90
In SYBYL/QSAR, the intensity of the crossvalidation process is controlled by 
selecting the number of groups, or the number of times the crossvalidation 
process is to be carried out while predicting all rows (at each stage of model 
development). If the number of groups is set to zero, crossvalidation is not 
performed. With the minimum number of groups, two, compounds will be 
divided into two groups, as equally sized as possible, and a model derived 
from each half will be used to predict target property values for the other half. 
The number of groups typically used in these studies is five, meaning that 
each target property value will be predicted by a model based on about 80% of 
the available data.
Currently, crossvalidation group membership is random, and cannot be 
controlled or even observed by the SYBYL/QSAR user. This randomness 
means that values of press and hence crossvalidated r2 will vary from run to 
run. Only by setting the number of crossvalidation groups equal to the number 
of compounds, so that every target property is predicted from all the other 
data, will these values be constant in consecutive runs.
The PRESS values are derived for models of increasing complexity, beginning 
with a 1-component model and computing up to a n-component model (n is 
set by the COMPONENTS option in PLS. An optimal number of components 
is reported as the number giving the smallest PRESS value. In practice, 
however, models with fewer components are more robust, and thus are to be 
preferred to models giving small decreases in PRESS. The final model was 
always obtained with the chosen number of components without 
crossvalidation, in order to make use of all available data.
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FACTOR ANALYSIS
Factor analysis describes a family of techniques for detecting simple linear 
structures by performing a multidimensional rotation on an arbitrary table of 
data. In the chemical context of a molecular modelling, the process can be 
seen fairly easily. For example, if you look at an arbitrarily orientated benzene 
molecule shown in figure 35, and consider that since benzene is planar, there 
must be some 3D rotation/translation operation which will make all its z-co- 
ordinates zero. Factor analysis identifies this rotation, and the other panels of 
figure 35 show graphs of the three main types of data produced by such a 
factor analysis. The upper right panel plots the scores: the benzene atomic co­
ordinates after simplification by factor analysis. The upper left panel plots the 
loadings: the elements of the rotation matrix which will convert the scores 
back into the original data. The lower left panel shows a bar graph of 
eigenvalues from this factor analysis, containing one line for each column of 
input data. Two of the lines are large and the third is miniscule, indicating that 
benzene is a flat molecule.
The aim of principal factor component analysis (FACTOR without the 
rotation of axes) is to find a new orthogonal co-ordinate system so that the 
sample variances with respect to these axes are maximised in decreasing 
order. In other words, the first new co-ordinate system describes the maximum 
variance among all possible directions, the second describes the next largest 
variance among all directions orthogonal to the first one, etc.
o 
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FIGURE 35 - Factor analysis of benzene co-ordinates.
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The success or failure of this operation is reported as a series of eigenvalues, 
the fraction of total variance orthogonal to each of the successive new factors, 
conventionally scaled so that the total of the eigenvalues equals the number of 
eigenvalues. If a much simpler data structure exists, the sum of the first few 
eigenvalues will be nearly equal to the number of eigenvalues. The ratio of 
this sum to this number is conceptually identical to the conventional (non­
crossvalidated) r2 value in a PLS or regression analysis.
The other important results of this operation are different matrices known as 
the loadings or eigenvectors and the scores. The loadings matrix has the same 
number of columns as the input data and has p rows (where p is the number 
of principal components obtained), while the scores matrix has p columns and 
the same number of rows as the input matrix. Matrix multiplication of the 
scores by the loadings restores the input data matrix. The scores matrix is 
essentially the objective of the factor analysis, i.e. the input data in a form 
simplified by the new co-ordinate system.
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PARTIAL LEAST SQUARES
Partial least squares is one of several techniques producing an equation, or 
QSAR, to describe or predict differences in the values in one or more table 
columns (the target properties) from differences in the values in other table 
columns (the explanatory properties). A more familiar example of such 
techniques is multiple regression (MR).
The outcome of PLS or MR is based on the knowledge about the explanatory 
properties to reduce uncertainty in the target properties. We may take the 
example of the case where it is desired to be able to predict the target property 
of some newly synthesised compound. In the absence of any other knowledge, 
the most reasonable guess for that value is would probably be the mean of all 
previous values, and the uncertainty of that guess would be the standard 
derivation of those values. The basic objective of any QSAR study is to find a 
predictive rule which performs better than this 'no rule at all1 guess of using 
the average deviation of the average.
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SOME QSAR TERMINOLOGY
Some of the basic terms used in QSAR terminology are:
s = a measure of the target property uncertainty still unexplained after the 
QSAR has been derived. Its magnitude depends also on the measurement 
scale for the target property;
r2 = the proportion of the original uncertainty which is explained by using the 
QSAR. Being a ratio, its magnitude is unaffected by the measurement scale.
F-ratio = the ratio of r2 to 1.0 - r2 (explained to unexplained), weighted so 
that the fewer the explanatory properties and the more the values of the target 
property, the higher the F-ratio.
residual = the difference between an actual target property and a calculated 
property. A large residual value indicates a compound that is not well 
modelled by the QSAR.
equation = the QSAR, a set of coefficients and an intercept or offset, used for 
prediction. An explanatory property value is supplies for each coefficient, and 
the prediction becomes the sum of the products of coefficient and explanatory 
property value, plus the intercept:
prediction = intercept + explanatory i*coefficienti + 
explanatory2*coefficient2 + explanatory3 *coefficient3  etc.
Whether crossvalidation is used in conjunction with PLS, some of the above 
indices meanings change slightly and others are omitted as meaningless. The
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key difference is in the definition of the s value. Usually s is the uncertainty 
remaining after the least-squares fit has been performed, but in 
crossvalidation, s becomes the uncertainty in prediction over all the 
compounds, often called PRESS. It is harder to predict values which are not 
used in deriving a model than it is to fit the same values while including them 
in a model, thus the 'predictive r2' is always worse than the conventional r2 
for the same data. The crossvalidation indices, however, are reported to be 
much better indicators of how accurate the predictions are likely to be.
PLS uses the crossvalidation principle to control its central loop, the iterative 
derivation of successive components. With each new component, the press is 
recomputed. Typically the first few components contain signal, a consistent 
relationship between target and explanatory properties, and the press decreases 
while the crossvalidated r2 increases. Eventually, however, additional 
components will only be fitting noise in the explanatory variables to noise in 
the target properties, this situation is signalled by an increase in press and a 
decrease in crossvalidated r2; the additional components are improving the fit 
between target and explanatory properties, but only by distorting coefficient 
values in a way which steadily worsens the predictive value of the QSAR. The 
optimal number of components correspond to the highest crossvalidated r2. If 
there are more than one dependent columns, the optimal number of 
components refers to the one with the highest sum of crossvalidated r2 derived 
for each component.
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The PRESS value can be given by:
Y
y  (Y p r e d  — Y a c t u a l ) 1 
and the formula for the predictive or crossvalidated r2 is :
Y
y  ( Y pred  — Y a c tu a l) 2
1 p
y  ( Y pred — Y m ean) 2
where YpRED is a predicted value;
Y ACTUAL is an actual or experimental value
y m e a n  is the best estimate of the mean of all values that might be
predicted;
the summations are over the same set of Y.
The crossvalidated standard error of estimate used is :
I PRESS 
V n - c - 1
where n = number of rows
c = number of components.
Once the model has been formed and validated, predictions are relatively 
straightforward to carry out. Each new molecule is built, added to the database 
in the same manner as the model compounds, with its orientation frozen and 
Del-re charges calculated. QSAR CoMFA ALIGNMENT DEFINE is then 
carried out to restrict and name the conformation of each new molecule. This 
ALIGNMENT is then VIEWED and QSAR ANALYSIS PREDICT is carried
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out under this named alignment. CoMFA fields are calculated automatically 
for the compound unless they have been calculated separately earlier, in which 
case when prompted 'USE PREVIOUS FIELDS (default no)' , one can reply 
yes. The field values are entered into the model equation and a value of 
biological activity based upon these is predicted.
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CoMFA RESULTS
The first four analogues of viridin synthesised were based on initial modelling 
studies and feasibility of synthesis (see Chapter 5) and are shown below.
O
OR
Rl=H r 2=o Demethoxyviridin [3]
Rl=H r 2=n -o h Analogue 1 [18]
Rl=OCOCH3 R2=0 Analogue 2 [19]
Rl=OCOCH2CH3 R2=0 Analogue 3 [20]
Rl=OCOCH2CH3 R2=0 Analogue 4 [21]
FIGURE 36 - The first four demethoxyviridin analogues synthesised.
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The first model built was from wortmannin analogues 1-10:
H3CO.
OO
OH
[1] Rl=OAc r 2=o r 3=h R4= c l o s e d  r in g
[12] Rl=OAc r 2=o r 3=o c o c h 3 R4= c l o s e d  r in g
[13] Rl=OAc r 2=o r 3=h R4=NHC6H5
[14] Rl=H r 2=o r 3=h R4= c l o s e d  r in g
[16] Rl=OAc r 2=o h r 3=h R4= c l o s e d  r in g
[17] Rl=H r 2=o h r 3=h R4= c l o s e d  r in g
[22] Rl=OAc r 2=c h =c h 2 R3=H R4= c l o s e d  r in g
[23] Rl=OAc r 2=o h r 3= c h 2 R4= c l o s e d  r in g
[24] Rl=OAc R2=ONO(OH) r 3=h R4= c l o s e d  r in g
[25] Rl=H R2=OCH2OCH3 r 3=h R4= c l o s e d  r in g
FIGURE 37 - The ten wortmannin analogues used to build a CoMFA model.
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The crossvalidated r2 for this study was 0.624 with a non-crossvalidated r2 of 
0.957. The results of the study are shown in the table below.
MOLECULE ACTUAL PREDICTED RESIDUAL
l/InlCso 1/lnICso
[11 0.690 0.747 0.057
[12] 0.410 0.392 0.018
[13] 0.333 0.333 0.004
[14] 0.529 0.539 0.010
[16] 0.813 0.751 0.062
[17] 0.513 0.499 0.014
[22] 0.513 0.523 0.010
[23] 0.476 0.491 0.015
[24] 0.444 0.436 0.008
[25] 0.357 0.373 0.016
TABLE 8 - Results from the CoMFA model study of wortmannin analogues.
As can be seen from the table above the predictions of activity are very 
accurate, with extremely small residual values. The standard error of estimate 
for these results is 0.046, with an F value of 17.783. The relative contributions 
from each variable (%) were 61.2% steric and 38.8% electrostatic. This 
suggests that both factors are important, although steric factors carry twice as 
much weight in this case. The electrostatic value is fairly high in comparison 
to other studies 64, where electrostatic contributions vary from only 8.0  to 
12.3%.
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From this model, predictions of synthesised analogues were carried out. 
The results are shown in table 9 below:
MOLECULE PREDICTED ACTUAL
I/I11IC50 I/I11IC50
VIRIDIN [2] 0.671 0.817
MOL1 [18] 0.561 0.353
MOL2 [19] 0.671 0.593
MOL3 [20] 0.707 0.940
MOL4 [21] 0.669 0.817
TABLE 9 - Predicted vs. actual results for the first analogues synthesised.
The resulting IC50S are based on different assays so the actual values are 
different. The correlation in order of potency, however, is good and 
regression analysis by partial least squares gives an r2 of 0.828. These results 
were very exciting because they showed not only that activity could actually 
be predicted, at least in terms of order of potency, but also suggested that there 
was perhaps a mechanistic link in the cytotoxic and anti-inflammatory action 
of these compounds, perhaps an increase in activity was activated by means of 
the same key enzyme.
From the reported result of a steroid binding study64 it was decided to build 
some wortmannin analogues based on the changes in the steroid structures 
which led to the highest increases in potency of binding to the receptor. This 
was based simply on the fact that wortmannin and viridin both have a very 
rigid steroid-like skeleton. Changes made to the steroids included the addition 
of a bulky group to ring D to increase lipophilicity, and therefore ease 
transport across membranes, addition of fluorine as a very electronegative
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influence to pull electrons away from the carbonyl group on ring A thereby 
making the oxygen more delta negative and more likely to bind to a delta 
positive hydrogen. Binding through these atoms was thought to be critical in 
the action of steroids. Other ideas such as introducing a corticoid side chain 
onto ring D or changing the furan oxygen to a nitrogen were also tried. The 
additional compounds overleaf were built and energy minimised.
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Molecule Ri R2 R3 R4 R 5 R6
[26] OAc o H N ring closed
[27] OAc o H S ring closed -
[28] OAc COCH2OAc H 0 ring closed -
[29] H COCH20H H 0 ring closed -
[30] OAc 0 COCH2OCOC1 H 0 ring closed -
[31] OAc DCOCH2OCOBr H 0 ring closed -
[32] OAc O H 0 ring closed F
[33] OAc O H c h 3 - -
[34] OAc O c h 3 0 ring closed -
[35] OAc O H OH CHN(Et)2 -
[36] OAc O H c h 2 ring closed -
[37] OAc O H F c h 3 -
[38] OAc (:o (c h 2)2C o c h 3 CH2Prl O ring closed -
FIGURE 38 - Theoretical wortmannin analogues.
OH
OH
Molecule Ri R 2 R3 r 4 R5 R6
[39] H o H N closed ring
[40] H o H - S closed ring
[41] H OCOCH2OAc H - O closed ring
[42] H o c o c h 2o h H - 0 closed ring
[43] H o c o c h 2o c o c 1 H - O closed ring
[44] H OCOCH2OCOBr H - O closed ring
[45] H 0 H F O closed ring
[46] H O H - OH c h 3
[47] H 0 c h 3 - O closed ring
[48] H OH H - OH CHN(Et)2
[49] H O H - F c h 3
[50] H CO(CH2)2COCH3 CH2Prt - 0 closed ring
FIGURE 39 - Theoretical viridin analogues.
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Hydrocortisone (cortisol) was also tested:
HO
-- - •O H
FIG U R E  40 - Hydrocortisone (cortisol) [51]
The predictions of biological activity of these molecules, based on the 
CoMFA model, is shown in the table overleaf.
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Molecule Actual IC50 Actual 
1/log IC50
Predicted IC50 Predicted 
1/log IC50
[11 28.1 0.690 22.6 0.738
[2 ] 3.4 1.881 29.8 0.678
[3] 1.5 5.679 28.8 0.685
[4] - - 28.8 0.685
[5] - - 58.9 0.565
[61 - - 32.6 0.661
[7] - - 29.6 0.680
[8 ] - - 3.7 0.760
[9] - - 28.7 0 .686
[101 - - 32.9 0.659
[111 - - 36.5 0.640
[121 274.8 0.410 256.8 0.415
[131 1000 0.333 44.1 0.608
[14] 77.7 0.529 81.0 0.524
[15] 1000 0.333 29.6 0.680
[16] 17.0 0.813 19.9 0.770
[17] 89.0 0.513 84.5 0.519
[18] 17.0 0.813 93.8 0.507
[19] 5.4 1.365 27.9 0.692
[2 0 ] 2.9 2.163 28.1 0.690
[2 1 ] 3.4 1.882 30.2 0.676
[2 2 ] 89.0 0.513 92.2 0.509
[23] 126.1 0.476 54.1 0.577
[24] 178.8 0.444 196.6 0.436
[25] 632.6 0.357 134.2 0.470
[26] - - 21.9 0.746
[27] - - 23.7 0.727
[28] - - 256.8 0.415
[29] - - 599.5 0.360
[30] - - 55.6 0.573
TABLE 10 - CoMFA predictions based on wortmannin model.
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Molecule
(cont.)
Actual IC50 
(cont.)
Actual
1/logICso
(cont.)
Predicted IC50 
(cont.)
Predicted 
1/log IC50 
(cont.)
[311 - - 330.3 0.397
[32] - - 68.4 0.545
[33] - - 54.5 0.576
[34] - - 52.5 0.582
[35] - - 48.3 0.594
[36] - - 63.8 0.554
[37] - - 54.5 0.576
[38] - - 345.2 0.394
[39] - - 28.8 0.685
[40] - - 28.8 0.685
[41] - — 36.1 0.642
[42] - - 35.9 0.643
[43] - - 37.6 0.635
[44] - - 37.1 0.637
[45] - - 27.2 0.697
[46] - - 28.8 0.685
[47] - - 28.0 0.691
[48] - - 27.6 0.694
[49] - - 27.2 0.697
[50] - - 69.4 0.543
[51] - - 206.4 0.432
TABLE 10 (cont.)- CoMFA predictions based on wortmannin model.
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The following compounds were also synthesised and predictions tested.
[52]
Molecule Ri R2 R3 Position 1,2
[53] OCOPh 0 O saturated
[54] OH 0 N(CH3)OH saturated
[55] OCOCH3 0 N-OH saturated
[56] OCOCH3 OH OH saturated
[57] - 0 O unsaturated
FIGURE 41 - Synthesised hibiscone C and demethoxyviridin analogues.
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The results from CoMFA predictions of these molecules are shown in the 
table below.
Molecule Actual
IC50
Actual
1/logICso
Predicted
IC50
Predicted
1/logICso
[52] 111.7 0.488 58.4 0.566
[53] 1.62 4.773 28.5 0.687
[54] - - 95.5 0.505
[55] - - 82.4 0.522
[56] - - 128.7 0.474
[57] 0.033 -0.675 28.0 0.691
TABLE 11 - CoMFA predictions of hibiscone C and demethoxyviridin 
analogues based on viridin model.
I l l
There are several points to note from all these predictions. The most active 
(actual) compounds were [31 demethoxyviridin with an IC50 of 1-5, [53] the 
synthesised viridin analogue with the phenyl group substituent and IC50 of 
1-62 and [57] the synthesised dehydro-viridin analogue with an IC50 of 0-033 
the most active compound to date. All three of these compounds were 
predicted to have an IC50 of around 28, which although is higher, is the lowest 
(and in the most active) range of predictions. The lowest predicted value was 
for [8 ] hibiscone C as a result of which, a synthesis of this molecule was 
attempted with a view to producing analogues for testing. The synthesis 
proved difficult, however, with a very low yield and the part structure 
synthesised [52] was almost totally inactive with an IC50 of 111-7. The part 
structure itself was predicted to be fairly active with an IC50 of 58-4. These 
results were disappointing, although a fairly large structural difference 
between hibiscone C and viridin analogues may account for the difference in 
activity. From these results it was seen, in particular, that a shortcut to active 
analogues would not be possible. It appears that the rest of the structure is 
required to stabilise what are thought to be the active centres.
Other compounds with predicted IC50S of less than 28 were [1] wortmannin, 
which was the second most potent compound in the anti-inflammatory test, 
[16] the wortmannin analogue with ring D carbonyl reduced, the most active 
in the test, so the correlation here was very good. Theoretical analogues with 
potent IC50S (less than 28) were [26] and [27], wortmannin analogues where 
the oxygen in the furan ring E is substituted with nitrogen or sulfur 
respectively. The two similarly modified viridin analogues [39] and [40] also 
had IC50S of about 28. Although this activity is identical to viridin, although 
slightly better than demethoxyviridin, this small change in structure may have 
been worth following up if time had allowed as the analogues may be more 
stable.
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Other theoretical analogues predicted to be particularly active included [48] 
and [49] with IC50S of 27*6 and 27-2 respectively. These compounds were 
'broken ring' analogues, however, so it was thought that in practice activity 
would be lost, as is the case for the anti-inflammatory analogues of 
wortmannin. This theory, however, has not yet been tested. Introducing a 
fluorine atom into ring B produced a theoretically active compound [45] with 
an IC50 of 27-2. This step was taken by workers in steroid binding studies 
where the electronegative fluorine was thought to draw electrons away from 
the carbonyl oxygen, thus making it more susceptible to hydrogen bonding at 
the receptor. In fact, the most potent orally active steroid to date is the fluorine 
containing compound betamethasone. This suggests perhaps this carbonyl is 
critically involved in binding to a receptor and that the electronegativity of the 
oxygen would be of fundamental importance.
Changes to the molecules which rendered them particularly inactive were, in 
general, the addition of bulky groups onto ring D, e.g. [12] the addition of 
OCOCH3 onto the position adjacent to the carbonyl of ring D of wortmannin 
increased the IC50 to over 250, as did the conversion of this carbonyl to a 
corticoid side chain. Other bulky substitutions as in molecules [31] and [38] 
increased the IC50 to over 330 and an extended corticoid group without the 
acetyl group in [29] led to an IC50 of almost 600. These results indicate that 
either shape or lipophilicity is critical at this position on ring D, perhaps even 
the receptor is not completely internalised by membrane so a very high 
lipophilicity is not necessary for binding.
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Following on from these results, the next logical step appeared to be to build a 
model from the viridin analogues themselves. This would mean the predicted 
activities of any new compounds would be directly relevant to cytotoxic 
activity. Nine molecules had the available cytotoxicity test data at this point, 
[2], [3], [18], [19], [20], [21], [52], [53], and [57]. An initial attempt to use all 
nine compounds was unsuccessful with a negative r2 resulting. Deletions of 
[53], shown to have a very high CoMFA value in the CoMFA column, [3] and 
[57] for reasons of having particularly high activities led to a crossvalidated r2 
of 0.601 with a final r2 of 0.874. The F value was 27.7. and the standard error 
of estimate was 0.025. The relative contributions from each variable were as 
follows:
Norm. Coefficient Fraction (%)
1. Autocomfa (STERIC) 0.153 15.3
2. Autocomfa 0.847 84.7
(ELECTROSTATIC)
TABLE 12 - Relative contributions from steric and electrostatic variables
(viridin model).
From the electrostatic (blue and yellow) and steric (red) map shown (Figure 
42) a strongly yellow region was seen around the top ring D suggesting that 
increased activity could be achieved by decreasing bulk around this region. A 
blue region was also apparent at this point, suggesting increased positive 
charge would be beneficial. A distinct red area around the carbonyl group in 
ring A suggests an increased negative charge at this point would be conducive 
to favourable activity e.g. addition of an electronegative influence such as 
fluorine.
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FIGURE 42 - Electrostatic (blue and yellow) and steric (red) map from viridin
CoMFA study.
Blue - increased positive charge 
Yellow - increased negative charge 
Red - decreased bulk
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A table of the activity and residuals of the viridin model is seen in table 13.
Molecule Actual
l/log(ICsoxlOO)
Predicted
l/log(IC5oxlOO)
Residual
[2 ] 0.40 0.39 0.01
[18] 0.31 0.28 0.03
[19] 0.37 0.39 -0.03
[20] 0.41 0.39 0.01
[21] 0.40 0.39 0.0018
[52] 0.25 0.27 -0.03
TABLE 13 - Actual vs Predicted activity results from viridin CoMFA model.
From this model, predictions were re-calculated as before, and are shown in 
Table 14 overleaf.
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Molecule Actual
IC50
Actual 
l/log(IC5ox 100)
Predicted
IC50
Predicted
l/doglCsoxlOO)
[11 28.1 0.290 4.1 0.382
[2] 3.4 0.395 3.8 0.387
[3] 1.5 0.500 6.8 0.353
[4] - - 3.9 0.286
[5] - - 49.9 0.270
[61 - - 4.1 0.382
[7] - - 3.9 0.385
[81 - - 4.4 0.378
[91 - - 4.1 0.382
[10] - - 3.9 0.386
[11] - - 3.9 0.384
[12] 274.8 0.225 21.7 0.300
[13] 1000 0 .200 16.8 0.310
[141 77.7 0.257 25.5 0.294
[15] 1000 0 .200 4.2 0.382
[16] 17.0 0.310 4.1 0.382
[17] 89.0 0.253 22.2 0.299
[18] 17.0 0.310 36.0 0.281
[19] 5.4 0.366 4.3 0.380
[20] 2.9 0.406 3.6 0.392
[21] 3.4 0.395 3.5 0.393
[22] 89.0 0.253 4.1 0.383
[23] 126.1 0.244 3.5 0.393
[24] 178.1 0.235 17.0 0.310
[25] 632.6 0.208 22.5 0.298
[26] - - 4.1 0.382
[27] - - 4.1 0.382
[28] - - 27.7 0.290
TABLE 14 - Predicted results from viridin model (continued overleaf).
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Molecule Actual
IC50
Actual
l/log(IC5oxlOO)
Predicted
IC50
Predicted
l/log(IC5oxlOO)
[29] - - 29.7 0.288
[30] - - 4.1 0.383
[31] - - 27.4 0.291
[32] - - 23.2 0.297
[33] - - 22.8 0.298
[34] - - 23.1 0.297
[35] - - 17.5 0.308
[36] - - 24.5 0.294
[37] - - 21.8 0.299
[38] - - 28.1 0.290
[39] - - 3.9 0.386
[40] - - 3.9 0.386
[41] - - 3.9 0.386
[42] - - 3.9 0.386
[43] - - 3.9 0.386
[44] - - 3.9 0.386
[45] - - 3.9 0.386
[46] - - 3.9 0.386
[47] - - 3.9 0.386
[48] - - 3.9 0.386
[49] - - 3.9 0.386
[50] - - 4.0 0.383
[51] - - 18.7 0.305
[52] 111.7 0.274 44.3 0.274
[53] 1.62 0.453 3.6 0.391
[54] - - 35.6 0.282
[55] - - 32.7 0.285
[56] - - 38.6 0.279
[57] 0.033 1.929 4.1 0.383
TABLE 14 - CoMFA predictions from viridin model (cont.).
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From this model there are also several points to note about the resulting 
predictions. The most active compounds [3], [53] and [57] were predicted to 
have IC50S of 6.8, 3.6 and 4.1 respectively (actual IC50S were 1.5, 1.62 and 
0.033) so again although activity for these extremely active compounds could 
not be predicted in terms of the actual value, the order of potency was 
apparently high. The lowest predicted value in this model was for [5], the 
'query' hibiscone-like structure with predicted IC50 of almost 50. This low 
activity was seen in practice. One of the main differences in this model was 
that hibiscone C [8 ] was predicted to be fairly active ( IC50 = 4.4). The actual 
part structure [52] synthesised, however, was predicted, and in fact was, very 
inactive (predicted IC50 = 44.3, actual = 111.7). This suggests that completion 
of the synthesis of hibiscone C, if time had allowed, may have been fruitful.
Wortmannin [1], and its hydroxy derivative [6 ] both had predicted IC50S of 
4.1, i.e. very active. Among the theoretical analogues, the highest activities 
were seen from the wortmannin [26] and [27] and viridin [39] and [40] 
analogues with substituted furan ring oxygen to a nitrogen or sulfur atom. 
Their predicted activities were comparable with wortmannin and only 
marginally worse than viridin.
Changes in the theoretical molecules which rendered them particularly 
inactive were as before, i.e. [29] IC50 = 29.7 when the furan ring is broken 
and a fluorine atom is introduced. Also seen in both models is a large decrease 
in activity associated with an increase in lipophilicity seen by substitution in 
ring D as in [38].
A recent publication explained the synthesis of a simplified analogue of 
wortmannin (shown below). Broka et al 74 found tested the analogue for its
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ability to block /-Met-Leu-Phe-stimulated generation of superoxide by 
neutrophils and found it to be inactive under conditions where wortmannin 
itself possessed an IC50 of 0 .1pm. It was therefore decided to build this 
molecule using SYBYL and predict its activity. In fact, SYBYL predicted an 
IC50 of 442pm for this compound, i.e. extremely inactive.
O
FIGURE 43 - Simplified wortmannin structure [58].
In general, the predicted results showed a good correlation with the actual 
results available.
CHAPTER 4 
CRYSTALLOGRAPHY
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BASIC THEORY
The primary aim of crystal structure analysis by X-ray diffraction is to obtain 
a detailed picture of the contents of the crystal at the atomic level. Once this 
information is available, and the positions of the individual atoms known 
precisely, one can calculate the inter-atomic distances, bond angles and other 
features of the molecular geometry that are of interest, such as polarity of a 
particular group of atoms, the angles between planes, and conformational 
angles around bonds. For the purposes of this project this information is used 
mainly as a tool for drug design, i.e. an attempt to relate structural features to 
chemical or biological properties.
X-rays are scattered by the electrons in atoms but in contrast to the situation 
with visible light, such radiation cannot normally be focused by presently 
known experimental techniques65. This is because no electrical or magnetic 
field or material exists that can refract X-rays sufficiently to form an X-ray 
lens. An alternative technique used in practice is to intercept the diffracted or 
scattered radiation by a detecting system, although the relationships between 
the phases of scattered waves are lost and only the intensities can be 
measured, therefore information is lost.
It is possible, however, to simulate the recombination of scattered X-rays by a 
mathematical calculation called a Fourier synthesis. This is a fundamental 
step in crystal structure determination. The major complication is referred to 
as the phase problem, i.e. discovering the relative phases of the diffracted 
beams that are needed to compute a recognisable image of the molecule. 
When these relative phases are known, the molecule will be revealed as a 
result of such a Fourier synthesis.
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CRYSTAL STRUCTURE OF DEMETHOXYVIRIDIN
Demethoxyviridin, C19H 14O5 , (figure 44), has been previously isolated from 
extracts of the mycelium of the unidentified fungus ACC3199. It also comes 
from Apiospora camptospora and Nodulisporum hinnuluem (ATCC24911)66. 
It is structurally related to several known metabolites including viridin, for 
which the crystal structure has been solved34. The crystal structure of 
demethoxyviridin therefore provides useful data for detailed comparison of 
these compounds.
O
OH
FIGURE 44 - Viridin R=OMe [2]
Demethoxyviridin R=H [3]
EXPERIMENTAL
The crystal sample donated by Wellcome consisted of pale yellow crystals of 
varying size, depth of colour and opacity. The chosen crystal was pale yellow 
and acicular, having dimensions 3*2 x 1*5 x 0-5 mm. Diffraction data were 
collected on an Enraf-Nonius CAD-4 diffractometer.
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CRYSTAL DATA
C19H 1 4 0 5 , M=321.31, orthorhombic space group P 2 i2 i2 ij a=8.47, b=19.33, 
c=17.91, V=2935 A3* Z=8 , Dx=1.454gcnr3, (CuK )=1.5418 A, ^ . ^ c n r 1, 
F(000)=668, final R=0.062 for 3158 unique observed reflections.
RESULTS
Structure solution was achieved by direct phasing methods using MITHRIL68. 
Least squares were used to refine lattice parameters. From an initial 25 
reflections, two standard intensities were chosen to monitor variations in 
intensity, < 3% variation was observed. The correct phasing was established 
only after a tricyclic ring system was incorporated into NORMAL with 
random position and orientation. 150 negative quartets were also used for both 
phase expansion and figures of merit. The resulting solution clearly indicated 
the positions of all the main atoms for one molecule. It was therefore decided 
not to recycle MITHRIL at this stage. Initial stages of least squares refinement 
resulted in a rise in the R factor from approximately 0.76 to around 2.2 
although it is not unusual for R to rise before dropping to a more realistic 
value. Block matrix refinement was repeated for a further 2 cycles until R was 
0.49. A difference Fourier map was then calculated to determine the positions 
of the H atoms. It became apparent at this stage that there were 2 molecules in 
the asymmetric unit. The main atoms for the second molecule were appended 
to the model file and refinement continued. Block matrix refinement was then 
rerun for a further 4 cycles without refining the temperature factors. This 
brought the R value down to 0.13 with several H atoms missing. Final 
refinement revealed the Hs and achieved a final R value of 0.062 for 3158
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unique observed reflections. All calculations were performed using the 
Glasgow GX package68.
DISCUSSION
Final positional and equivalent isotropic thermal parameters are given in 
Appendix 1. Bond lengths, bond angles and torsion angles are listed in 
Appendices 2, 3 and 4 respectively. An ORTEP47 diagram, Figure 45 
illustrates the numbering scheme for the molecule. Figure 46 shows a 
stereoview of the cell contents.
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FIGURE 44 - ORTEP48 diagram of demethoxyviridin showing the numbering 
scheme with vibrational ellipsoids at 50% probability level.
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FIGURE 45 - Stereoview of demethoxyviridin unit cell contents.
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DESCRIPTION OF MOLECULE
There are two molecules in the asymmetric unit which are identical within 
experimental error. Analysis using molecular graphics revealed the molecule 
to be largely planar. Each molecule was identical around the two chiral centres 
present.
The atoms best describing the planes for each of the 5 rings are listed in Table 
15. Deviations from these same planes were examined by Neidle, Rogers et al 
for viridin34 These deviations are compared to viridin and listed in Table 16. 
The largest of these is seen in ring D. This observation was confirmed in 
molecular graphics experiments docking the two molecules together using 
HYDRA. It was found that the basic structures are almost identical but ring D 
and to a lesser extent ring C had changed conformation slightly as a result of 
the removal of the methoxy group on C(2). There was no apparent difference 
in ring A.
RING ATOMS
A C(2) C(3) C(4) 0(21)
B C(6) C(7) C(8) 0(24)
C C(8) C(9) C (ll) C(12) C(13) C(14)
D C(13) C(14)C(17) 0(18)
E C(4) C(5) C(6) C(22) 0(24)
TABLE 15 - Atoms best describing the planes of demethoxyviridin.
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RING ATOM DEMETHOXYVIRIDIN VIRIDIN
A C(l) 0.001 0.000
C(3) -0.004 0.002
C(4) 0.001 0.000
0 (21) 0.001 -0.001
B C(6) -0.005 -0.003
C(7) 0.016 0.011
0 (8) -0.005 -0.003
0(24) -0.005 -0.004
C C(8) -0.006 -0.004
C(9) 0.004 0.000
C (ll) 0.001 0.004
0 (12) -0.004 -0.004
0(13) 0.002 0.000
0(14) 0.004 0.004
D 0(13) -0.008 0.001
0(14) 0.011 -0.001
0(17) -0.028 0.003
0(18) 0.017 -0.002
E 0(4) -0.011 -0.011
0(5) 0.012 0.019
0 (6) -0.014 -0.020
0 (22) 0.003 -0.001
0(24) 0.004 0.013
TABLE 16 - Deviations (A) from planes compared to viridin.
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Many of the conformational features of demethoxyviridin are due to the strain 
induced by the unique unsaturated ring E, on the A and B rings. Ring A is 
buckled and ring B is a slightly flattened boat with both bow and stem 
deflected B to the main plane of the molecule. Ring C is benzenoid and ring D 
is flat and essentially co-planar with C. Ring E is also flat. This basic 
molecular shape can also be applied to the viridin molecule.
Ring A is perhaps best described as a distorted chair cyclohexenone, with C(l) 
and C(4) deflected respectively above and below the plane. Ring B shows 
considerable deviations from the usual geometry of a cyclohexadienone. C(5), 
C(6 ), C(8) and C(9) are closely co-planar, with C(7) and C(10) displaced 
0.116A and 0.219A respectively from the plane. These values are comparable 
for viridin, i.e. 0.108A and 0.304A respectively. This ring can be best 
described as a slightly flattened boat. Steric considerations probably play a 
major role in the case of demethoxyviridin, with angular strain on the ABE 
ring junctions producing a situation in which ring B is forced to pucker and 
adopt a boat shape.
Ring C is a typical benzene ring although substituents C(7) and C(10) are 
displaced slightly out of plane, probably due to ring fusion strain mentioned 
above.
Ring D is almost planar with C(15) being displaced 0.0321A above the plane 
of the ring. This shift may be due to the proximity of 0(24).
Ring E is a furan ring and is planar within experimental error although its 
substituents C(3) and C(7) lie below the plane. The angles between the planes 
are essentially indicative of a largely planar structure (Table 17 overleaf).
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PLANE ANGLE (°)
A-B 170.45
A-E 171.95
B-E 12.79
B-C 171.40
C-D 177.26
TABLE 17 - Angles between the planes of the rings.
The entire crystal structure consists of infinite chains of molecules linked by a 
single hydrogen bond between O(20)-H and 0(18), spiralling around the a 
axis, packed in a zigzag arrangement of chains (Fig. 47).
FIGURE 47 - Repeated unit cells of demethoxyviridin.
CHAPTER 5 
ORGANIC SYNTHESIS
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1. SYNTHESIS OF A HIBISCONE C ANALOGUE
From a computer search of the Cambridge crystallographic database 
(Chapter 2), one of the compounds retrieved by use of the query structure 
was hibiscone C [8 ], a furanosesquiterpene. This compound was isolated 
independently by Pelter69 (as gmelofuran from the roots of Gmelina 
aborea) and Thomson71 (as hibiscone C from the heartwood of Hibiscus 
elatus, or the Blue Mahoe, national tree of Jamaica) in the late 1970s. The 
compounds were later shown to be identical. The structure (shown below) 
represents an analogue of the tricyclic furan part of demethoxyviridin, 
viridin and wortmannin.
This compound was synthesised by A.B. Smith HI et al in 198471 and is a 
member of a small group of tricyclic furanosesquiterpenes that now 
includes hibiscone A [59], B [60], D [61] and agarol [62], the latter being 
independently isolated in the late 1970s70.
FIGURE 48 - Hibiscone C [8] (Gmelofuran)
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Molecule Hi R2
Hibiscone A [59] 
Hibiscone B [60] 
Hibiscone D [61] 
Agarol [62]
h 2
a-OH, B-H 
O 
O
O
O
a-OH, B-H 
OH
FIGURE 49 - Other tricyclic furanosesquiteipenes.
The key architectural feature of this family, the tricyclofuran ring skeleton, 
is thought to be critical for the cytotoxic activity of the more complex 
fungal antibiotics wortmannin [1] and viridin [2]. Attempts to obtain a 
sample of hibiscone C [8 ] for testing this hypothesis were unsuccessful 
therefore it was decided to synthesise the molecule according to the 
published method with a view to producing several structural analogues.
Interest in hibiscone C [8 ] as a synthetic target stemmed from the 
realisation that the tricyclic nucleus might be assembled from intermediate 
[65] via a novel [2+2] photocycloaddition of the acetylenic moiety to the 
enone functionality (Figure 50). The resultant cyclobutene [64] was then
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exploited as a latent furan by a sequence of oxidative cleavage to a 1,4- 
dicarbonyl compound and acid catalysed cyclisation/dehydration to the 
furan [63]. Further elaboration, i.e. introduction of a carbonyl group at 
C(2) and then the axial methyl at C(3) led to racemic hibiscone C [8]. The 
synthesis proceeded in 10 steps with an overall yield of 2.5%.
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[65]
.0
[63]
Me
[64]
FIGURE 50 - Retrosynthesis of hibiscone C [8 ].
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It was decided to attempt the synthesis of the simplified hibiscone C 
analogue [6 6 ], as this retained what were thought to be the main structural 
features for biological activity.
FIGURE 51 - Simplified hibiscone C analogue [66 ].
The reaction scheme for this synthesis is outlined in Figure 52.
The enol ether of dihydroresorcinol is formed using ethanol and p-toluene 
sulphonic acid. This compound then undergoes alkylation with 5-iodo-l- 
pentyne, and is further reduced then hydrolysed in one step to form the 
cyclohexenone. Photolysis of this compound produces an unstable 
cyclobutene ring which is easily opened during subsequent ozonolysis to 
produce the tricyclic hibiscone C analogue [72] (for experimental details 
see Appendix 6).
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+ C2H£)H 
'OH
[67]
[68]
1.LDA
2.HMPA
3. ICCH^C:
O
iCH
l.LiAlH,
21^ [69]
[70]
[71]
[72]
FIGURE 52 - Reaction scheme for hibiscone C analogue [72].
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This compound, however, showed little or no cytotoxic activity and was 
not seen to inhibit the specified enzymes in biochemical tests. A second 
dicarbonyl analogue,[73] synthesised by a fellow postdoctoral worker74, 
was also shown to be inactive.
FIGURE 53 - Dicarbonyl hibiscone C analogue [73].
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2. SYNTHETIC STUDIES TOWARDS WORTMANNIN
A report by workers in California74 describes the first synthesis of the 
highly reactive furanocyclohexadienone lactone sub-unit of wortmannin
These workers acknowledged that wortmannin had been shown to 
inhibit / - Met-Leu-Phe stimulated superoxide production75 and 
phospholipase D activation76 in human neutrophils, perhaps by disrupting 
the function of the GTP-binding protein involved in the transduction of the 
/-Met-Leu-Phe signal. In spite of their interesting biological activities and 
challenging structures, these compounds have received little synthetic 
attention. This fact may be due, in part, to their chemical instability which 
promises to complicate efforts towards their synthesis. The route 
published circumvents many of these difficulties and should prove 
versatile enough to allow for the preparation of wortmannin itself.
(Fig. 54).
FIGURE 54 - Simplified wortmannin structure [74].
The retrosynthetic analysis is outlined overleaf in Figures 55, 56 and 57.
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MeO
WORTMANNIN [1]
HO
OMe
I
[75]
OH
ROMeO
OH
[76]
OH
FIGURE 55 - Retrosynthetic analysis of wortmannin. 
(continued overleaf)
140
HO
OH
[77]
OH
[78]
v
[79]
FIGURE 56 - Retrosynthetic analysis of wortmannin. 
(cont. overleaf)
[79]
[80]
I
H
FIGURE 57 - Retrosynthesis of wortmannin (cont.)
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The idea to use [75] as a precursor for the synthesis of wortmannin came 
from investigation by workers at Sandoz.77 It was shown that wortmannin 
is an active alkylating agent, reacting with ammonia, aniline and 
diethylamine to give derivatives exactly analogous to [75]. In contrast to 
wortmannin, these aminomethylene lactones are stable to a range of 
nucleophilic conditions. Furthermore, treatment of these materials with 
acid regenerates wortmannin. Thus these lactones may be thought of as 
protected forms of wortmannin, a fact which may be of major importance 
if these compounds are to be delivered to the body as drugs (see Chapter 6 , 
Discussion). In fact, the preparation of these compounds was considered 
by Broka et al to be the equivalent to the preparation of wortmannin itself. 
It seemed reasonable that [75] could be obtained from the diol lactone [76] 
and that this compound could in turn be obtained from the Diels-Alder 
derived intermediate [77]. The workers did not, however, wish to 
undertake such a lengthy synthesis without the prior assurance that the key 
transformations outlined would take place. Accordingly, the simplified 
wortmannin analogue [74] (Fig. 54), which still contains the reactive 
functionality present in natural systems, was selected as an initial target. 
This compound was synthesised in 13.5% overall yield.
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3. SYNTHESIS OF DEMETHOXYVIRIDIN ANALOGUES
Following from the recently published synthesis of wortmannin, this 
approach, rather than that of Smith III et a l , was adopted in the synthesis 
of a number of demethoxyviridin analogues by a postdoctoral student also 
involved in this project. The analogues synthesised are shown below 7^.
Molecule Ri R2 R3 Position 1,2
[181 OH N-OH O saturated
[19] OCOCH3 O 0 saturated
[20 ] OCOCH2CH3 O O saturated
[21 ] OCO(CH2)2CH3 O O saturated
[53] OCOPh O O saturated
[54] OH N(CH3)OH O saturated
[55] OCOCH3 N-OH O saturated
[56] OCOCH3 N-OH OH saturated
[57] - O O unsaturated
FIGURE 58 - Demethoxyviridin analogues synthesised.
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4. BIOSYNTHESIS
Although neither viridin or wortmannin have been synthesised there has 
been extensive study into the biosynthesis of these compounds. In 196978 
Grove et al realised that the structure of viridin strongly suggested a 
steroidal biogenetic pathway
The biosynthesis of steroids may be divided into two main phases79. The 
first phase involves the assembly of the prenyl pyrophosphate units, from 
mevalonic acid, into two head to head condensed famesyl pyrophosphate 
units and subsequent formation of squalene oxide and cyclisation to 
lanosterol (see Figs. 59 and 60 overleaf). The second phase involves the 
oxidative degradation and rearrangements of C30 lanosterol to give the 
individual families of steroids.
FIGURE 59 (overleaf) - Formation of squalene from famesyl PP.
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OPP
Famesyl PP 
[82]
OPP
OPP
NADPH*
*H
FIGURE 59 - Formation of squalene [83].
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The cyclisation of squalene is initiated by the acid catalysed ring-opening 
of squalene mono-epoxide, and may be a completely concerted process, or 
perhaps interrupted at some intermediate stage to allow rearrangement to 
occur.
Squalene
[83] NADPH
Squalene
epoxide
[84]
(chair-boat-chair-boat)
FIGURE 60 - Epoxidation of squalene.
The cyclised molecule then undergoes rearrangement to form lanosterol 
and degradation to form various other steroids such as cholesterol, sex 
hormones, bile acids and vitamin D.
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Squalene 
epoxide [84]
HO
%
%
%
Lanosterol [85]HO
FIGURE 61 - Generation of lanosterol [85].
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Biosynthetic studies of viridin have been fairly extensive. It was known 
that [14C]viridin, derived from [2-14C]mevalonate, had a labelling pattern 
consistent with its biogenesis by tail-to-tail condensation of two famesyl 
residues.78 The steroidal biogenetic pathway of viridin was shown to be 
from (R)-mevalonic acid [86 ] by way of famesyl pyrophosphate, squalene 
epoxide [84] and lanosterol [85].
Biosynthetic studies of wortmannin were undertaken by a Simpson et a/80 
in 1979. By enrichment of Penicillium dangeardii cultures with sodium 
[l,2 -13C2]acetate, it was shown that the biogenesis of this metabolite was 
consistent with the anticipated pathway via triterpenoid intermediates. 
Like viridin, the acetate was incorporated via mevalonic acid, squalene, 
and lanosterol.
FIGURE 62 - (R)-Mevalonic acid [86].
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CONCLUSION
A variety of techniques has been employed to provide valuable detailed 
structural information about this series of fungal metabolite analogues 
with potential novel cytotoxic mechanisms of action .
The extraction of viridin from Trichoderma viride was optimised and 
carefully monitored until the yield was increased four fold. This was fairly 
low, however, so synthesis of part structure analogues was attempted. 
Also, attention was turned to the fungus Nodulisporum hinnuleum which 
generated high yields of demethoxyviridin. Although the synthesis of part 
structure analogues was in itself successful, the compounds produced were 
shown to be inactive. A more rational approach was then adopted by 
means of computer modelling and drug design. A QSAR model was built 
using S YBYL which enabled prediction of activity of new molecules. This 
study enabled guiding in the synthesis of new molecules and was 
eventually a contributing factor in the synthesis of a molecule several 
hundred times more active than the lead compound.
Much encouraged by this result, a patent is being applied for this analogue 
while consideration is being made of the stability required to enable 
formulation of the drug to a form acceptable for administration to animals 
and for phase 1-ID clinical trials in humans.
CHAPTER 6 
DISCUSSION
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DISCUSSION
1. EXTRACTION
If time had allowed, a greater degree of optimisation of the extraction 
conditions may have afforded a higher yield of viridin, i.e. the growing 
medium may have been changed to determine the optimum nutrients 
required for maximum growth and production of viridin by the fungus. 
More detailed pH or temperature studies may have been beneficial. 
Growth may also have been simplified by growing in one fermentation 
vessel if the necessary equipment was available.
Growth and extraction of wortmannin from Penicilliwn dangeardii was 
delayed due to several contaminated batches of fungus being sent from 
Kew initially. The extraction is now in process.
The extraction of demethoxyviridin from Nodulisporwn hinnuleum proved 
to be much more viable. Reported literature yields81 were approaching lg 
compound per litre of broth. The production of this compound is now 
being undertaken on a large scale at SmithKline Beechams1 production 
plant.
2. CRYSTALLOGRAPHY
The crystal structure determination of several more analogues is now in 
progress. The structures assume that the conformation adopted by the 
molecules in the unit cell is similar to that in solution as it is the most 
energetically favourable. To investigate how realistic this assumption was, 
a model of viridin was built and energy minimised using SYBYL, and
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compared to a structure derived from the imported crystal co-ordinates 
from the Cambridge Structural Database. The structures were found to be 
exacdy the same when overlapped. This may be due to the rigidity of these 
types of molecules. Their planar and pentacyclic ring structure does not 
lend itself to conformational changes. For other, less rigid molecules, 
differences may well be expected between crystal structure and energy 
minimised model.
3. MODELLING
Initial modelling studies were based on the assumption that the anti­
inflammatory structure-activity relationship of the wortmannin analogues 
would be at least in some way directly related to the cytotoxicity test 
results of these compounds. This assumption was taken in the absence of 
any other test data, and because wortmannin had a roughly similar order of 
potency in both the anti-inflammatory test system and in cytotoxicity tests. 
This assumption, in fact, turned out to be justified and it was shown that 
molecules which had a predicted activity according to the wortmannin 
anti-inflammatory model had the same order, if not magnitude, of potency 
when predicted by the cytotoxic viridin model.
The building and validation of this model could then predict activities of 
new compounds, before they were synthesised, and was a central part of 
this project allowing the synthetic efforts to be guided in a more rational 
way.
A more helpful situation would obviously be where the identity and 
structure of the target protein is known, i.e. where and how exactly the 
molecules are binding. The solubilisation and purification of 
phospholipase D, with a view to crystallisation and determining the crystal
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structure, is in process in the Biochemistry department. Rat-tissue 
phospholipase D has previously been purified82. It is becoming 
increasingly apparent with recent results, however, that the target proteins 
may be tyrosine kinase. The planar structure of the molecules themselves 
suggest they are binding in a cleft or groove of a particular protein. In the 
future, an unambiguous way to determine where they are binding would 
obviously be to identify, purify and crystallise the target protein, 
determine the crystal structure with and without the compound bound to 
its active site, and compare the two.
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4. SYNTHESIS
From the viridin, demethoxyviridin and wortmannin structures, and the 
knowledge that all anti-inflammatory activity of wortmannin is lost when 
the furan ring is broken, this furan flanked by two carbonyl groups is 
thought to be central to the activity of these compounds. Modification of 
existing lead compounds to establish a structure-activity relationship was 
established by computer modelling studies. Results to date suggest that the 
more planar the molecule, the higher its biological activity. This, again, 
may be due to its binding into a narrow cleft in a protein.
Synthesis of an analogue of hibiscone C, was successful although the 
molecule itself was not active. A second approach to the problem is to 
synthesise a number of furan derivatives containing suitable functional 
groups in order to attempt to build up the minimum structure for activity. 
Derivatives of demethoxyviridin such as the 1-epimer, derivatisation at 
C l, functionalisation of ring D and modification of the furan ring are 
being synthesised. Crystal structure determination of these analogues will 
be performed in order to assist in modelling studies.
Thus a combination of different techniques has led to the design, synthesis 
and testing of analogues several hundred times more active than the 
original lead compound. The synthetic efforts are now being directed 
towards the problems of stability.
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PROBLEMS OF STABILITY
These compounds are very unstable in an aqueous environment at pH 
greater than 5, with a half life in the order of minutes, and so would rapid 
degradation at physiological pH would be expected. Presuming their 
stability, e.g. expressed as half-life in solution at certain pH, is structure 
dependent, the possibility exists to model these compounds using the 
CoMFA technology, in order to predict stability.
To deliver these compounds as drugs would present numerous problems. 
The entire formulation process would have to be strictly pH controlled 
with the only obvious stable form of drug as a freeze dried powder for 
reconstitution and injection. Appropriate time stability studies would be 
necessary to indicate stability of the compound in the solid state, although 
data so far suggests little degradation takes place. A light stability study 
may also be appropriate since increased production of the compound by 
the fungus is seen in the dark, possibly due to photo-degradation in the 
light. This may necessitate storage of the compound in amber or light 
resistant vials.
The very short half life of the compound may necessitate protection of the 
drug until it reaches the target site. Here, a variety of drug delivery 
methods may come into play, e.g. pro-drugs or carrier vehicles.
The compound could be delivered as an inactive pro-drug, e.g. with a 
broken ring (see Chapter 5), to reduce the chances of hydrolysis in the 
bloodstream. This derivative would have to be designed so that it is 
released at the active site as an active drug. This method would need more 
detailed studies of precise mechanism of action a particular enzymes could
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be used as a means to cleave the functional group from the pro-drug and 
allow recyclisation of the furan. Some of the broken ring adducts, e.g., 
those produced on reaction of wortmannin or viridin with diethylamine, 
are stable to many forms of nucleophilic attack and easily recyclise in the 
presence of acid. This would suggest the stomach as an ideal site of 
release and a possible way to treat stomach cancer.
The drug could also be delivered by means of a carrier, protected from the 
external aqueous environment by a hydrophilic matrix, e.g. liposomes or 
cyclodextrins. This vehicle would still need to be delivered to the active 
site. This may happen via normal bloodstream flow, although problems of 
poor tissue perfusion and decreased blood flow are often seen at the site of 
a solid tumour, one method of targeting therefore may involve attachment 
of a semi-synthetic antibody for a particular protein to several molecules 
of drug. A problem, again, with this method is the difficulty in achieving 
sufficient loading of the antibody with enough drug to produce a 
therapeutic effect. The affinity of the drug to the antibody must be 
maximised. Problems of rejection of this foreign body by the body's 
immune system must also be overcome. Although site specific delivery is 
ideal in theory, in practice it can be fraught with difficulties.
Additional formulation problems which may be foreseen are non- 
homogenous particle size. This may necessitate salt formation or 
experimenting with different salts and conditions of crystallisation to 
achieve the desired result. Compatibility with excipients, e.g., diluent, 
glidant, coating agent of a tablet formulation , would be assessed as well 
as possible interactions with other drugs.
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Cancer patients are often on a complex multiple dosage system comprising 
many different drugs which are administered concurrently or at optimum 
intervals to provide least depression of the white blood bell count. If a new 
drug is to be introduced into this complex regimen, all possible 
interactions or cumulative side effects must be carefully assessed to 
maximise benefit and minimise risk to a patient.
In conclusion, the studies reported in this thesis have guided and led to the 
synthesis of a compound not only with high cytotoxic activity but also a 
possible novel mechanism of anti-cancer action which would provide 
selectivity of action in future clinical trials.
APPENDICES
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APPENDIX 1
TABLE 1 - Fractional atomic co-ordinates and isotropic temperature factors 
(angstrom squared), with standard deviations in the least significant digits in 
parentheses. For anisotropic atoms, the equivalent isotropic temperature 
factors are shown (continued overleaf).
ATOM X/A Y/B ZIC U
C(l) 0.1452(4) 0.1651(2) 0.8683(2) 0.030
C(2) 0.2305(4) 0 .1022(2) 0.9012(2) 0.039
C(3) 0.4079(4) 0.0961(2) 0.8895(2) 0.039
C(4) 0.4833(4) 0.1614(2) 0.8717(2) 0.033
C(5) 0.3953(3) 0.2237(2) 0.8691(2) 0.027
C(6) 0.4911(4) 0.2730(2) 0.8416(2) 0.032
C(7) 0.4437(4) 0.3424(2) 0.8204(2) 0.030
C(8) 0.2664(4) 0.3510(2) 0.8220(2) 0.028
C(9) 0.1632(4) 0.3007(1) 0.8535(2) 0.027
C(10) 0.2265(3) 0.2343(2) 0.8910(2) 0.026
C (ll) 0.0021(4) 0.3142(2) 0.8551(2) 0.032
C(12) -0.0613(4) 0.3746(2) 0.8268(2) 0.036
C(13) 0.0382(4) 0.4228(2) 0.7955(2) 0.034
C(14) 0.2032(4) 0.4120(2) 0.7924(2) 0.032
C(15) 0.2824(5) 0.4709(2) 0.7526(2) 0.042
C(16) 0.1532(5) 0.5234(2) 0.7375(3) 0.048
C(17) -0.0011(5) 0.4913(2) 0.7645(3) 0.044
C(19) 0.2169(4) 0.2457(2) 0.9767(2) 0.037
C(22) 0.6307(4) 0.1778(2) 0.8479(2) 0.041
0(18) -0.1309(4) 0.5172(2) 0.7625(2) 0.067
0 (20) -0.0167(3) 0.1619(2) 0.8890(2) 0.040
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TABLE 1 - Fractional atomic co-ordinates and isotropic temperature factors 
(angstrom squared), with standard deviations in the least significant digits in 
parentheses. For anisotropic atoms, the equivalent isotropic temperature 
factors are shown (continued).
ATOM X/A Y/B z/c U
0 (21) 0.4767(4) 0.0411(2) 0.8941(2) 0.063
0(23) 0.6394(3) 0.2462(1) 0.8291(2) 0.040
0(24) 0.5343(3) 0.3876(1) 0.8005(2) 0.046
C(l') 1.0163(4) 0.2549(2) 0.5627(2) 0.033
C(2') 1.0829(4) 0.3246(2) 0.5891(2) 0.039
C(3') 0.9623(5) 0.3823(2) 0.6063(2) 0.039
C(4') 0.8076(5) 0.3549(2) 0.6267(2) 0.039
C(5') 0.7782(4) 0.2822(2) 0.6296(2) 0.032
C(6’) 0.6213(4) 0.2744(2) 0.6409(2) 0.050
C(7f) 0.5378(4) 0.2118(2) 0.6375(2) 0.050
C(8 ') 0.6375(4) 0.1531(2) 0.6098(2) 0.050
C(9') 0.8031(4) 0.1602(2) 0.5950(2) 0.050
C(IO') 0.8962(4) 0.2256(2) 0.6191(2) 0.050
C (ll’) 0.8856(4) 0.1047(2) 0.5635(2) 0.050
C(12') 0.3119(5) 0.4564(2) 0.4557(2) 0.050
C(13') 0.6522(5) 0.0365(2) 0.5589(2) 0.050
C(14') 0.5632(4) 0.0898(2) 0.5915(2) 0.050
C(15') 0.3940(5) 0.0687(2) 0.6008(3) 0.050
C(16') 0.3829(5) -0.0033(2) 0.5665(3) 0.050
C(17') 0.5462(5) -0.0224(2) 0.5424(2) 0.050
C(19') 0.9750(4) 0.2080(2) 0.6942(2) 0.050
C(22') 0.1656(5) 0.1137(2) 0.3628(3) 0.050
0(18’) 0.5886(4) -0.0773(1) 0.5134(2) 0.050
0 (20’) 1.1462(3) 0.2108(1) 0.5488(2) 0.050
0 (21 ') 0.9939(4) 0.4430(1) 0.5998(2) 0.050
0(23’) 0.5488(3) 0.3389(1) 0.6459(2) 0.050
0(24’) 0.3975(3) 0.2056(1) 0.6526(2) 0.050
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APPENDIX 2
TABLE 2 - Bond lengths (A) of both molecules of demethoxyviridin
compared to viridin.
BOND MOLECULE 1 
Demethoxyviridin
MOLECULE 2 
Demethoxyviridin
VIRIDIN
C(l) - C(2) 1.534(5) 1.536(5) 1.537
C(l)-C(10) 1.559(5) 1.563(5) 1.554
C(l) - 0(20) 1.422(4) 1.414(5) 1.417
C(2) - C(3) 1.522(6) 1.544(6) 1.518
C(3) - C(4) 1.451(5) 1.461(6) 1.441
C(3) - 0(21) 1.216(5) 1.210(5) 1.213
C(4) - C(5) 1.416(5) 1.427(5) 1.427
C(4) - C(22) 1.357(5) 1.361(6) 1.376
C(5) - C(6) 1.346(5) 1.354(5) 1.348
C(5) - C(10) 1.498(5) 1.474(5) 1.490
C(6) - C(7) 1.541(5) 1.403(5) 1.444
C(6) - 0(23) 1.377(5) 1.393(5) 1.398
C(7) - C(8) 1.512(5) 1.499(5) 1.491
C(7) - 0(24) 1.216(5) 1.225(5) 1.229
C(8) - C(9) 1.425(5) 1.435(5) 1.402
C(8) - C(14) 1.398(5) 1.415(5) 1.424
C(9) - C(10) 1.545(5) 1.536(5) 1.538
C(9) - C (ll) 1.390(5) 1.399(5) 1.409
C(10) - C(19) 1.553(5) 1.553(5) 1.538
C (ll) - C(12) 1.381(5) 1.380(6) 1.374
C(12) - C(13) 1.377(5) 1.385(6) 1.387
C(13) - C(14) 1.415(6) 1.404(5) 1.393
C(13) - C(17) 1.474(5) 1.480(6) 1.478
C(14) - C(15) 1.502(5) 1.500(6) 1.500
C(15) - C(16) 1.518(6) 1.524(6) 1.533
C(16) - C(17) 1.526(7) 1.496(6) 1.510
C(17) - 0(18) 1.209(6) 1.235(5) 1.218
C(22) - 0(23) 1.367(5) 1.358(5) 1.368
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APPENDIX 3
TABLE 3 - Bond angles (°) of both molecules of demethoxyviridin compared
to viridin (continued overleaf).
BOND MOLECULE 1 
Demethoxyviridin
MOLECULE 2 
Demethoxyviridin
VIRIDIN
C2-C1-C10 112.3(4) 111.7(3) 114.8
C10-C1-020 112.9(4) 114.3(3) 112.6
C2-C3-C4 113.7(5) 113.3(3) 113.4
C4-C3-021 125.0(5) 124.9(4) 124.8
C3-C4-C22 133.3(5) 132.2(4) 132.3
C4-C5-C6 107.2(5) 106.4(3) 107.7
C6-C5-C10 125.7(5) 125.4(3) 124.2
C5-C6-023 110.2(5) 110.6(3) 110.4
C6-C7-C8 112.1(4) 112.4(3) 111.4
C8-C7-024 123.5(5) 123.8(4) 125.4
C7-C8-C14 118.8(5) 118.7(3) 117.9
C8-C9-C10 122.2(4) 120.7(3) 120.9
C10-C9-C11 119.3(4) 119.0(3) 118.3
C5-C10-C9 108.9(4) 108.9(3) 108.6
C9-C10-C19 106.7(4) 106.2(3) 106.6
C11-C12-C13 119.0(5) 119.5(4) 118.0
C12-C13-C17 128.6(6) 128.9(4) 127.5
C8-C14-C13 120.8(5) 120.2(4) 118.6
C13-C14-C15 109.5(5) 110.6(4) 111.7
C15-C16-C17 106.8(5) 106.2(4) 106.2
C13-C17-018 126.1(6) 125.5(4) 125.3
C4-C22-023 110.9(5) 111.3(4) 111.7
C2-C1-020 108.9(4) 107.9(3) 108.9
161
TABLE 3 - Bond angles (°) of both molecules of demethoxyviridin compared
to viridin (continued).
BOND MOLECULE 1 
Demethoxyviridin
MOLECULE 2 
Demethoxyviridin
VIRIDIN
C1-C2-C3 118.4(5) 116.6(3) 117.1
C2-C3-021 121.2(5) 121.8(4) 121.4
C3-C4-C5 120.8(5) 121.0(4) 121.3
C5-C4-C22 105.6(5) 106.4(4) 105.1
C4-C5-C10 127.1(5) 128.1(4) 128.1
C5-C6-C7 125.7(5) 125.5(4) 125.6
C7-C6-023 123.9(5) 123.4(4) 123.8
C6-C7-024 124.3(5) 123.6(4) 123.1
C7-C8-C9 122.1(5) 123.1(3) 123.7
C9-C8-C14 119.1(5) 118.0(3) 118.3
C8-C9-C11 118.4(5) 120.2(3) 120.6
C1-C10-C5 104.2(4) 104.6(3) 105.3
C1-C10-C19 111.4(4) 110.0(3) 112.1
C5-C10-C19 109.2(4) 110.4(3) 110.2
C9-C11-C12 122.3(5) 120.7(4) 121.3
C12-C13-C14 120.4(5) 121.4(4) 123.3
C14-C13-C17 111.0(5) 109.6(4) 109.2
C8-C14-C15 129.6(5) 129.3(4) 129.7
C14-C15-C16 105.3(5) 105.1(4) 104.9
C13-C17-C16 107.2(5) 108.4(4) 107.9
C16-C17-018 126.6(6) 126.1(4) 126.9
C6-023-C22 106.0(4) 105.4(3) 105.1
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APPENDIX 4
TABLE 4 - Torsion angles of both molecules of demethoxyviridin (continued
overleaf).
TORSION
ANGLE
MOLECULE 1 
Demethoxyviridin
MOLECULE 2 
Demethoxyviridin
Cl 0-1-2-3 -51.3(4) -54.9(4)
C2-1-10-5 52.7(3) 53.0(3)
C2-1-10-9 172.8(4) 173.3(4)
C2-1-10-19 -64.3(4) -65.5(4)
O20-C1-2-3 -177.2(5) -178.8(5)
O20-C1-10-5 176.0(4) 175.0(4)
020-C1-10-9 -63.9(3) -64.7(4)
020-C1-10-19 59.0(3) 56.6(3)
C l-2-3-4 20.6(4) 25.4(4)
C l-2-3-021 -158.7(6) -151.3(6)
C2-3-4-5 2.3(4) 0.2(4)
C2-3-4-22 -169.9(6) -171.0(6)
021-C3-4-5 -178.5(6) -176.8(6)
021-C3-4-22 9.3(5) 5.6(5)
C3-4-5-6 -171.7(5) -172.7(5)
C3-4-5-10 7.2(4) 4.8(4)
C3-4-22-023 171.7(6) 171.7(7)
C22-4-5-6 2.3(4) 0.5(4)
C22-4-5-10 -178.7(5) -178.0(5)
C5-4-22-023 -1.3(3) -0.5(4)
C4-5-6-7 171.5(5) 171.0(5)
C4-5-6-023 -2.5(3) -0.4(3)
C4-5-10-1 -34.8(4) -31.5(4)
C4-5-10-9 -159.6(5) -156.8(5)
C4-5-10-19 83.4(4) 86.6(4)
C6-5-10-1 144.0(4) 145.5(5)
C10-5-6-7 -7.5(4) -6.6(4)
163
TABLE 4 - Torsion angles of demethoxyviridin (continued overleaf).
TORSION
ANGLE
MOLECULE 1 
Demethoxyviridin
MOLECULE 2 
Demethoxyviridin
C6-5-10-9 19.1(4) 20.2(4)
C6-5-10-19 -97.8(4) -96.4(5)
Cl 0-5-6-023 178.5(5) 177.9(5)
C5-6-7-8 -8.4(4) -7.4(4)
C5-6-7-024 174.6(6) 175.2(7)
C5-6-023-22 1.7(3) 0.1(4)
023-C6-7-8 164.8(5) 162.9(5)
C7-6-023-22 -172.5(5) -171.5(5)
023-C6-7-24 -12.1(4) -14.5(4)
C6-7-8-9 10.6(3) 5.0(4)
C6-7-8-14 -170.8(5) -169.5(5)
024-C7-8-9 -172.4(6) -177.6(6)
024-C7-8-14 6.2(4) 7.9(4)
C7-8-9-10 2.2(3) 10.1(3)
C7-8-9-11 177.5(5) 174.8(5)
C7-8-14-13 -177.7(5) -174.0(5)
C7-8-14-15 5.2(4) 5.2(4)
C14-8-9-10 -176.4(5) -175.3(5)
C 14-8-9-11 -1.1(4) -0.3(4)
C9-8-14-13 1.0(4) 0.7(4)
C9-8-14-15 -176.1(6) -179.9(6)
C8-9-10-1 -133.0(4) -139.2(5)
C8-9-10-5 -16.0(3) -21.1(3)
C8-9-10-19 102.2(4) 97.9(4)
C8-9-11-12 0.4(4) 1.7(4)
Cl 1-9-10-1 51.7(4) 45.8(4)
Cl 1-9-10-5 168.6(4) 163.9(5)
C10-9-11-12 175.9(5) 176.8(6)
Cl 1-9-10-19 -73.1(4) -77.1(4)
C9-11-12-13 0.4(4) -2.0(4)
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TABLE 4 - Torsion angles of both molecules of demethoxyviridin
(continued).
TORSION
ANGLE
MOLECULE 1 
Demethoxyviridin
MOLECULE 2 
Demethoxyviridin
Cll-12-13-14 -0.5(4) -0.9(4)
Cll-12-13-17 -177.7(6) 178.5(7)
Cl 2-13-14-8 -0.2(4) 0.4(4)
C12-13-14-15 177.4(5) 179.8(6)
C12-13-17-16 179.8(6) 177.7(6)
C12-13-17-18 1.2(5) 2.1(4)
C17-13-14-8 177.4(5) 177.6(5)
C17-13-14-15 -4.9(4) 1.8(4)
C14-13-17-16 2.4(4) 0.1(4)
C14-13-17-18 -176.3(6) -179.9(6)
C8-14-15-16 -177.3(6) -176.4(6)
C13-14-15-16 5.4(4) -2.9(4)
C14-15-16-17 -3.7(4) -2.8(4)
C15-16-17-13 1.0(4) 1.8(4)
C15-16-17-18 179.6(6) 178.4(6)
C4-22-023-6 -0.2(4) -0.2(4)
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APPENDIX 5 
VIRIDIN [2]
O
OH
(Rf = 0.47) M. Pt. 222-224°C, NMR: HI, 4.45 (J=5Hz); H2, 3.95; H ll, 
8.10 (J=8Hz); H12, 8.80, H15, 2.90; H16, 3.80; H18, 1.73; H19, 8.45; 
H20, 3.75. Calculated molecular weight: 352; found 352.
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APPENDIX 6
ORGANIC SYNTHESIS - EXPERIMENTAL
1. 3-ETHOXY-2-CYCLOHEXENONE [68 ]
O
Into a flask fitted with a Dean Stark apparatus was placed a solution of 
dihydroresorcinol (5.3g), p-toluene sulphonic acid (0.23g) and absolute 
ethanol (25ml) in benzene (90ml )84. The mixture was heated to boiling 
and the azeotrope composed of toluene, alcohol and water was removed at 
the rate of 10ml per hour. When the temperature of the distilling vapour 
reached 78°C after 6-8 hours, the distillation was stopped and the residual 
solution washed with portions of 10% aqueous sodium hydroxide (4 x 
10ml) saturated with sodium chloride. The resulting organic solution was 
washed with successive portions of water (5ml) until the aqueous 
washings were neutral and then concentrated under reduced pressure to 
produce dihydroresorcinol monoethyl ether (3-ethoxy-2-cyclohexenone) 
[68 ]. (4.06g, 76.6%): IR (CCI4) 3010 (s), 2940 (s ) , 1740 (s), 1710 (s), 
1230 (s), 1190 (s) cm-l; NMR (CDCI3, 90MHz) 5.2 (s, 1H), 3.75 (q, 2H), 
2.2 (t, 4H), 1.85 (m, 2H), 1.2 (t, 3H); mass calculated for C8H12O 12: 140; 
found 140.
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2. 3-ETHOXY-6-(4-PENTYNYL)-2-CYCLOHEXANE [69]
EtO
The next step was an alkylation using 5-iodo-l-pentyne as the alkylating 
agent85 . All glassware was flame dried under vacuum before starting the 
reaction. To a solution of diisopropylamine in 5ml dry THF (0.91ml) at 
0°C under vacuum was added n-butyl lithium (4.91; 1.6M). After 15 
minutes at 0°C, the solution was cooled to -78°C and 3-ethoxy-2- 
cyclohexenone [6 8 ] (0.92g) in 2.5ml THF was added dropwise over 45 
minutes via syringe. The reaction mixture was then allowed to warm up to 
-40°C and HMPA (1.6g) in THF (2ml)was added followed by 5-iodo-l- 
pentyne (1.91g). This was allowed to warm to 25°C then left at this 
temperature for a further hour. Saturated ammonium chloride (about 10ml) 
was then added and the organic phase diluted with hexane (approximately 
2 0ml), washed with water, dried using magnesium sulphate and 
concentrated under reduced pressure to give 3-ethoxy-6-(4-pentynyl)-2- 
cyclohexenone [69]. (1.36g 71.3%): IR (CCI4 ) 3320 (s), 2940 (s), 2100 
(w), 1660 (s), 1610,1380 (s), 1200cm-l; NMR (CDCI3, 250MHz) 1.34 (t, 
J = 6.8 Hz, 3H), 1.4-2.24 (m, 10H), 2.4 (t, J = 5.8 Hz, 2H), 3.9 (q, J = 6.8 
Hz, 2H), 5.26 (s, 1H); mass calculated for Ci3HisO2:206; found 206.
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3. 4-(4-PENTYNYL)-2-CYCLOHEXENONE [70]
The next stage was a 2 step 1,3-carbonyl transposition by first reducing the 
carbonyl in [69] with lithium aluminium hydride, followed by hydrolysis 
of the enol ether to the ketone then elimination to form [70]. 3-Ethoxy-6- 
pentynyl-2-cyclohexenone [69] (0.92g) in THF (2.5ml) was added 
drop wise to a stirred suspension of UAIH4 (0.13g) in THF (10ml) under 
nitrogen, the reaction mixture was stirred at 25°C for two hours. Excess 
hydride was destroyed by addition of solid sodium sulfate decahydrate. 
Water (2.5ml) was then added followed by sufficient 2N HC1 to adjust the 
pH of the aqueous phase to 2 (approximately 3ml). The reaction mixture 
was again left to stir for 30 minutes, the organic phase removed and 
washed with saturated sodium bicarbonate and brine and dried to give
[70]. (0.199g; 21.5%):IR (CCI4) 3320, 3020 (w), 2940 (s), 1685 (s), 1250, 
900 (s), 620 cm '1; NMR (CDCI3, 250 MHz) 1.98 (t, J = 2.5 Hz, 1H), 1.5- 
2.56 (m, 11H), 6.0 (dd, J = 10, 2.5 Hz, 1H), 6.86  (d, J = 10 Hz, 1H); mass 
calculated for Ci 1H 140 : 162; found 162.
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4. la, 3,4,4a, 5,6,7 ,7b-0CTAHYDR0-2H- 
CYCLOBUT[<fe]NAPTHALEN-2-ONE
[71]
Photolysis of [70] produces an intramolecular [2+2] cycloaddition of the 
enone and the acetylene to form a cyclobutene [71] which acts as a latent 
furan. The ketone [70] (200mg) was irradiated for 6 hours in acetonitrile 
(400ml) under nitrogen. A Pyrex glass filter was used to minimise the 
incidence of unwanted side reactions. Prior to the irradiation, nitrogen was 
bubbled through the acetonitrile solution for 15 minutes. The solution was 
evaporated to dryness and the product purified by column chromatography 
to give [71]. (480mg; 32%): IR (CCI4 ) 3050 (w), 2940 (s), 1710 (s), 
900cm-1; NMR (CDCI3, 250 MHz) 1.4-1.8 (m, 4H), 2.0-2.3 (m, 6H), 2.6 
(d, J = 14 Hz, 1H), 3.0 (s, 1H), 3.35 (m, 1H), 5.54 (s, 1H); mass calculated 
forC nH ^O : 162; found 162..
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5. 4,5,5a,6,7,8-HEXAHYDRO-3//-NAPTHO[l,8-£c]FURAN-3-ONE
[72]
Ozonolysis then introduces the oxygen into the furan to form [72], Ozone 
was bubbled into a solution of [71] (500mg) in dry dichloromethane 
(20ml) at -78°C for about 2 hours until the solution turned blue. After 
bubbling ozone through for an additional 5 minutes after the colour 
change, excess ozone was removed by bubbling nitrogen into the solution 
for 20 minutes until the blue colour had disappeared. Dimethyl sulphide 
(2ml) was added dropwise and the solution allowed to warm slowly to 
room temperature with stirring. The solution remained stirring at room 
temperature for a further 4 hours then the solvent removed by evaporation. 
A solution of the crude product in benzene (50ml) containing tosic acid 
(lOOmg) was then refluxed for 5 hours using a Dean Stark apparatus. The 
solution was allowed to cool and washed with sodium bicarbonate solution 
and brine, dried and evaporated to give the crude product [72]. (10%): IR 
(CCI4) 3150 (w), 2940 (s), 2850, 1690 (s), 1530, 1190, 1120cm-l; NMR 
(CDCI3 , 250 MHz) 1.18 (m, 1H), 1.48 (m, 1H), 1.9 (m M), 2.06-2.24 (m, 
3H), 2.44-2.8 (m, 5H), 7.82 (s, 1H); mass calculated for CnHi2C>2:176; 
found: 176.
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APPENDIX 7
Melting points were determined on a Kofler hot-stage apparatus and are 
uncorrected.
Infra-red spectra were recorded for potassium bromide discs on a Perkin- 
Elmer 983 spectrophotometer. The following abbreviations are used: s - 
strong, w - weak, br - broad.
Proton nuclear magnetic resonance spectra were measured at 200MHz on 
a Bruker AM200 S Y or a Bruker NP 200 SY spectrometer and at 90Hz on 
a Perkin-Elmer R32 or a Varian EM390 spectrometer. Carbon nuclear 
magnetic resonance spectra were determined at 50MHz on a Bruker 
AM200 SY or a Bruker WP200 SY spectrometer in the pulsed FT mode. 
DEPT editing was used to assist peak assignment. Spectra were recorded 
in deuteriochloroform with tetramethylsilane as internal standard. The 
following abbreviations are used: s - singlet, d - doublet, t - triplet, q - 
quartet, m - multiplet and b - broad.
Mass spectra were obtained using a MS 12 or MS 902 spectrometer.
Flash chromatography was carried out on silica gel HF254 and TLC on 
0 .2mm silica gel 6OF254.
Tetrahydrofuran was freshly distilled from sodium/benzophenone. Organic 
solutions were evaporated on a rotary evaporator under reduced pressure; 
solutions in organic solvents were dried over anhydrous magnesium 
sulfate.
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